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°C degree Celsius 
aa  amino acid  
Ab antibody 
ALT  alanine aminotransferase  
amp  ampicillin  
APS  ammonium persulfate  
BM Bone marrow 
BSA  bovine serum albumin  
BZB  bortezomib  
cFLIP  cellular FLICE inhibitory protein  
CRC  colorectal cancer  
CSCs cancer stem cells 
Da / kDa  (kilo) Dalton  
DAPI 4',6-diamidino-2-phenylindole 
Db  diabody  
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DISC  death-inducing signal complex  
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DNA  deoxyribonucleic acid  
dNTP  deoxyribunucleoside triphosphate  
DR  death receptor  
e.g.  exempli gratia / for example  
EC50  mean effective concentration  
ECL enhanced chemiluminescence 
EDTA  ethylenediaminetetraacetate  
EGFR  epidermal growth factor receptor  
ELISA  enzyme-linked immunosorbent assay  
f.c.  final concentration  
FBS fetal bovine serum 
FCS fetal calf serum 
Fig. figure 
FITC  fluorescein isothiocyanate  
G418 Geneticin 
h  hour  
His6  hexahistidyl  
HPLC  high performance liquid chromatography  
HRP  horse radish peroxidase  
hu  human  
i.p.  intraperitoneal  
i.v.  intravenous  
IBMX 3-isobutyl-1-methylxanthine 
IF immunofluorescence 
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MFI  mean fluorescence intensity  
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MW  molecular weight  
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PAGE  polyacrylamide gel electrophoresis  
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PCR  polymerase chain reaction  
PE  Phycoerythrin  
Pen/Strep Penicillin/Streptomycin 
ph Potential of hydrogen 
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rpm  rotation per minute  
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s.c. subcutaneous 
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SCs stem cells 
scTRAIL  single-chain TRAIL  
SDS  sodium dodecyl sulfate  
SDS sodium dodecyl sulfate 
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SEC  size exclusion chromatography  
SEM standard error of the mean 
SM Smac mimetic 
TEMED  N,N,N’,N’-tetramethylethyl-diamine  
TGF-β transforming growth factor β 
TNF  tumor necrosis factor  
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Summary  
 
Despite extensive studies aimed to increase the outcomes of cancer therapies, the 
conventional treatments still show lack of selectivity, short in vivo half-life and innate or 
acquired resistance. In this context, the discovery of cancer stem cells (CSCs), a small 
population within the tumor (<2-5 %) derived from normal stem cells after 
genetic/epigenetic alterations, defined new perspectives in the field of tumor therapy. In 
fact, due to their particular features, such as quiescent status and stemness properties, 
emerging data suggest a key role of CSCs in chemotherapy resistance, tumor relapse and 
metastasis formation. A promising strategy is the targeted delivery of anticancer proteins 
to CSCs, such as TNF-related apoptosis inducing ligand (TRAIL), in order to improve the 
therapeutic effects.  
Based on these new findings, in the first part of this study, two novel antibody single-chain 
(sc)TRAIL fusion proteins with hexavalent TRAIL assembly, targeting the cancer stem cell 
markers CD133 and LGR5, were generated and characterized (DbαCD133-scTRAIL and 
DbαLGR5-scTRAIL). The biochemical analyses demonstrated for both fusion proteins 
integrity and correct dimeric assembly. The binding functionality of the scTRAIL fusion 
proteins to the targets was confirmed by flow cytometry analysis. Furthermore, in order to 
investigate the bioactivity of the fusion proteins, TRAIL-mediated cell death induction was 
verified by in vitro assays. A significant increase of cell death induction was observed for 
both proteins which exerted even a more potent antitumoral effect in combination with the 
sensitizer Bortezomib, resulting in a ~4-fold increased bioactivity. Interestingly, a 
significant benefit of the targeting domains, in terms of enhanced binding rate or 
bioactivity, was not observed for both TRAIL fusion proteins in comparison with a non-
targeted TRAIL fusion protein. This is probably due to the particular cell lines tested, a 
moderate affinity of the targeting domain or to a low antigen expression on the two 
analyzed tumor cell lines. 
 
An alternative approach to enhance the efficacy of therapeutics is based on normal adult 
stem cells used as carrier system for the in situ production of proteins, resulting in higher 
local concentration and reduction of general side effects caused by systemic 
administrations. This method, which exploits unique properties of adult stem cells, such as 
mesenchymal stem cells (MSCs), including tumor homing capacity and 
immunosuppressive ability, is currently exploited as transient expression system for 
therapeutic proteins in clinical applications. In the second part of this work, this novel stem 
cell based approach for colon cancer treatment was investigated. Different from the 
published work, here, I investigated the potential use of MSCs as delivery vector for the 
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stable expression of the pro-apoptotic protein DbαEGFR-scTRAIL. First, the insensitivity of 
MSCs to TRAIL activity was verified, showing a complete resistant phenotype even in the 
presence of sensitizers, confirming the huge advantage of these cells. Then, the 
bioactivity of DbαEGFR-scTRAIL secreted by MSCs was analyzed and a potent cell death 
induction, caused by TRAIL apoptotic pathway activation, was observed in combination 
with bortezomib. Importantly, all MSC properties and characteristics were maintained after 
stable transfection over time in in vitro cultivation. Finally, using xenotransplantation 
mouse tumor models, I could demonstrate the therapeutic activity of DbαEGFR-scTRAIL 
produced by MSCs when injected peritumorally, in combination with Bortezomib. In fact, a 
significant tumor volume reduction and a survival rate of 80% was observed in 
comparison with all control groups. Interestingly, no hepatotoxic or general side effects 
were revealed during the entire period of treatment, indicating the safety of this novel 
therapeutic approach. 
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Zusammenfassung 
 
Trotz großer Fortschritte in der Onkologie gibt es für viele Tumorerkrankungen noch 
unzureichende therapeutische Ansätze, wofür u.a. Tumorheterogenität, konstitutive oder 
erworbene Resistenz des Tumors gegenüber dem Therapeutikum, fehlende Selektivität 
der Wirkstoffe und kurze in vivo-Halbwertszeit ursächlich sein können. In diesem 
Zusammenhang ist die Entdeckung von Krebsstammzellen (cancer stem cells, CSC), 
einer kleinen Population innerhalb des Tumors (2-5 %), die sich von normalen 
Stammzellen nach genetischen und epigenetischen Veränderungen ableiten, interessant. 
Krebsstammzellen wird aufgrund ihrer besonderen Stammzell-ähnlichen Eigenschaften 
eine Schlüsselrolle in der Therapieresistenz, insbesondere im Hinblick auf Tumorrückfall 
nach primärem Ansprechen sowie Metastasierung, zugeschrieben. Aufgrund der 
Unempfindlichkeit von Krebsstammzellen gegenüber konventioneller Chemotherapie 
könnte die gezielte Behandlung mit hochpotenten Proteintherapeutika, wie dem 
Apoptose-induzierenden Liganden TRAIL, eine erfolgversprechende neue Strategie 
darstellen. 
Basierend auf diesen aktuellen Erkenntnissen wurden im ersten Teil dieser Arbeit zwei 
neue, zielspezifische Antikörper-TRAIL-Fusionsproteine auf der Basis von einzelkettigem, 
single-chain (sc)TRAIL entwickelt. Die Fusionsproteine besitzen, die Spezifität für die 
Krebsstammzellmarker CD133 oder LGR5 sowie eine hexavalente Anordnung von TRAIL 
mit Hilfe des sogenannten Diabody-Formates (DbαCD133-scTRAIL und DbαLGR5-scTRAIL). 
Die biochemischen Analysen zeigten eine korrekte Assemblierung der jeweiligen 
Diabody-scTRAIL-Moleküle als Dimer, d.h. jedes Fusionsprotein-Molekül enthält zwei 
funktionelle, einzelkettige scTRAIL-Moleküle. Die spezifische Bindung der TRAIL-
Fusionsproteine auf den Zielzellen wurde mittels Durchflusszytometrie-Analyse und die 
Bioaktivität durch in vitro Apoptose-Induktion bestätigt. In beiden Fällen, DbαCD133-scTRAIL 
und DbαLGR5-scTRAIL, führte die simultane Inkubation der Zellen mit dem Proteasom-
Hemmstoff Bortezomib (Velcade) zu einer signifikanten (~4-fachen) Erhöhung der 
Apoptose . Überraschenderweise wurde aber für die untersuchten Zelllinien in den in vitro 
Experimenten kein Vorteil der zielspezifischen scTRAIL-Fusionsproteine gegenüber 
einem funktionell äquivalenten, nicht zielspezifischen scTRAIL-Fusionsprotein festgestellt. 
Die Gründe hierfür bleiben unklar, könnten aber in einer unzureichenden Expression des 
Zielproteins bzw. unzureichenden Affinität der scFv-Domäne für das Zielantigen 
begründet sein.  
 
Ein alternativer Ansatz, um die Wirksamkeit von Therapeutika zu verbessern, basiert auf 
normalen adulten Stammzellen, die als Trägersystem für eine in situ-Produktion von 
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Proteintherapeutika genutzt werden sollen., Die Verwendung dieser Zellen stellt vor allem 
unter dem Gesichtspunkt einer höheren lokalen Wirkstoff-Konzentration und Verringerung 
von allgemeinen Nebenwirkungen, wie sie bei systemischer Verabreichung oft beobachtet 
werden, einen Vorteil dar. Die einzigartigen Eigenschaften von adulten Stammzellen, 
insbesondere der mesenchymalen Stammzellen (MSCs), wie beispielsweise Tumor-
Homing-Kapazität und Gewebeverträglichkeit, machen diese Zellen zu einem attraktiven 
Werkzeug in der Tumortherapie. Im zweiten Teil dieser Arbeit, wurde deshalb ein 
Stammzell-basierter Ansatz für die Tumor-Behandlung in einem Darmkrebs-Modell 
untersucht. Insbesondere wurde die Verwendung von MSCs als stabiles 
Expressionssystem für die in situ-Herstellung des pro-apoptotischen Proteins DbαEGFR-
scTRAIL getestet. Es konnte gezeigt werden, dass die verwendete MSC-Linie 
unempfindlich gegenüber TRAIL und dem Antikörper-scTRAIL-Fusionsprotein und damit 
als Producer-Linie geeignet ist. Stabile Produktions-Klone konnten isoliert und in 
Langzeitkultur gehalten werden. Das sezernierte Produkt, DbαEGFR-scTRAIL, wies die 
erwarteten Eigenschaften bezüglich Apoptoseinduktion auf den entsprechenden Zielzellen 
auf. Von besonderer Bedeutung war die Beobachtung, dass die stabilen MSC-Klone alle 
phänotypischen und funktionellen Eigenschaften einer mesenchymalen Stammzelle 
beibehielten. Schließlich konnte in einem Xenotransplantations-Tumormodell der Maus 
die therapeutische Aktivität der peritumoral applizierten, DbαEGFR-scTRAIL produzierenden 
MSCs gezeigt werden, wobei die Wirkung durch zusätzliche Gabe des sog. „Apoptose-
Sensitizers“ Bortezomib deutlich gesteigert werden konnte. In dieser Behandlungsgruppe 
wurde im Beobachtungszeitraum (52 Tage) die stärkste Tumorvolumenreduktion und eine 
Überlebensrate von 80% festgestellt, im Vergleich zu den Kontrollgruppen (PBS 0%, 
Kontroll-MSC plus Bortezomib 50%, TRAIL-MSC ohne Bortezomib 60%). 
Interessanterweise wurden in den behandelten Tieren keine erhöhten Leberwerte oder 
allgemeine Nebenwirkungen festgestellt, was darauf hinweist, dass die Verwendung von 
mesenchymalen Stammzellen zu einem gut verträglichen Therapieverfahren entwickelt 
werden kann. 
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1 Introduction 
 
1.1 Colorectal cancer 
 
Cancer is the second cause of death worldwide and colorectal cancer (CRC) is the fourth 
most common lethal malignancy with over one million new cases every year (Siegel et al., 
2014). The normal intestinal epithelium presents a well-defined structure that consist of 
crypts and finger-like protrusions (villi) with a hierarchical organization. Due to the function 
of the organ, the homeostasis of this tissue is finely regulated.  
The CRC carcinogenesis is a multistep process that requires the accumulation of specific 
genetic mutations involved in various signal transduction pathways that maintain the 
correct intestinal homeostasis. The progression from normal colon tissue to adenoma, 
carcinoma and finally to metastatic cancer requires the sequential alteration of protective 
pathways regulated by adenomatous polyposis coli (APC), p53 and transforming growth 
factor β (TGF-β) and the activation of oncogenes such as K-Ras and B-Raf (Markowitz et 
al., 2009 and Lampropoulos et al., 2012) (Figure 1). An important characteristic of CRC is 
its high heterogeneity which can explain the wide range of different responses of patients 
to clinical therapy of tumors that are pathologically similar (Budinska et al., 2013).  
 
 
Figure 1 Schematic representation of colon carcinogenesis 
Mutations on APC gene, negative regulator of the Wnt pathway, leads to hyper proliferation and formation of 
an early adenoma. Alterations on BRAF and KRAS genes occurs at the stage of intermediate adenoma. Late 
adenoma results after loss of heterozygosity at 18q, including Smad 4, cell division cycle 4 (CDC4) and DCC. 
The invasive state, finally, occurs after mutations on p53, Bax, and/or insulin-like growth factor receptor 2 
(IGF2R) genes. Taken from Todaro et al., 2010. 
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Currently, the conventional strategies used to treat CRC are basically four: surgery, 
chemotherapy, radiotherapy and targeted therapies. Despite of the fact that surgical 
resection and additional therapy can cure early stage of primary tumors, the metastatic 
stage is mostly incurable because of its systemic distribution and resistance to 
conventional therapies. For this reason, more than 90% of cancer-related deaths can be 
ascribed to recurrence and not to primary lesions (Gupta et al., 2006 and Steeg et al., 
2006). In particular for patients with newly diagnosed metastatic colon cancer the 5 year 
prognosis continues to be less than 20% (Jemal et al., 2011). 
 
1.1.1 Stem cells and intestinal stem cell niche 
 
Stem cells (SCs) are defined as undifferentiated cells with indefinite ability for self-renewal 
and differentiation into various cell types. The first identification was reported in 1963 by 
Becker and Siminovitch (Becker et al., 1963 and Siminovitch et al., 1963). Stem cells can 
divide through two different mechanisms: symmetric division giving rise to two daughter 
cells identically to the mother cell that maintain the self-renewal capacity or through the 
asymmetric division producing one cell that is identical to the mother cell whereas the 
other one is a more specialized cell. Based on their ability to differentiate into various 
distinct cell types/tissues, i.e. their plasticity, stem cells are classified as totipotent, 
pluripotent and multipotent. The totipotent stem cells are found in the zygote and can 
generate a new individual on their own. The pluripotent stem cells can give rise to almost 
all body tissues but they lost the ability to form extraembryonic tissues like placenta. While 
the multipotent stem cells, also called adult stem cells (ASCs), can generate different cell 
types according to their location. These multipotent stem cells can be isolated from 
different adult tissues such as blood, epidermal and intestinal tissue characterized by 
rapid regeneration, where they contribute to maintain the tissue homeostasis (Beddington 
et al., 1989). In particular the colon, the last part of the digestive system, consists of 
millions of crypts and each one contains about 2000 cells (Potten et al., 1992 and Booth 
et al., 2000) which undergo turnover every 2-5 days in normal condition and increasing 
following tissue damage with an average of 1010 cells produced daily (Brittan et al., 2002). 
This complex process is regulated by adult stem cells located at the very base of the 
crypt. This specific environment is called Stem Cell Niche and consists of cellular and 
extracellular components that ensure the optimal condition for SC maintenance. In 
particular, the niches control the SC’s fate, regulating the correct balance between self-
renewal and differentiation, through the secretion of various cytokines, growth factors and 
direct interactions (Todaro et al., 2010). SCs in the niche divide mainly through 
asymmetric division generating one daughter identically to the mother that remains within 
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the niche and the other one that leaves the niche and differentiates along the crypt axis 
towards the luminal surface where it undergoes apoptosis (Todaro et al., 2010). Intrinsic 
and extrinsic factors have been shown to regulate SC niches. Merlos-Suarez et al. 
reported that ephrinB (EphB) pathway is involved in the cell compartments organization 
and in the regulation of migration of epithelial cells along the crypt axis (Merlos-Suarez et 
al., 2008). Intestinal subepithelial myofibroblasts (ISEMFs), located at the base of the 
crypt, are key regulators of intestine SCs by secreting a wide range of morphogenetic 
factors (Todaro et al., 2010). But the entire intestinal homeostasis is finely regulated by a 
complex crosstalk network of pathways such as Wingless/Int (Wnt), Notch and Hedgehog 
which control the balance between proliferation, differentiation and self-renewal. In 
particular for Wnt pathway there is a decreasing gradient of expression from the base to 
the top of the crypt. For this reason Wnt proteins are mainly present at the bottom of the 
crypt where they interact with receptors on epithelial cells resulting in nuclear translocation 
of β-catenin. Nuclear β-catenin induces the expression of EphB receptors which interact 
with ephrin ligands distributed along the crypt axis, enhancing the proliferation rate. In 
addition to Wnt signal Notch contributes to potentiate proliferation and inhibits 
differentiation at the bottom of the crypt (Holmberg et al., 2006). While Hedgehog pathway 
seems to be a Wnt suppressor, probably through BMP’s activity. In fact, there is a 
decreasing gradient of BMP expression from the top to the base of the crypt which 
neutralizes the proliferative effect of Wnt and maintains the differentiation state in the 
apical part of the crypt (Medema et al., 2011). This intricate network of finely regulated 
pathways defines the environment which controls the crucial balance between 
proliferation, differentiation and self-renewal in the intestinal tissue. In this context, 
obviously, the alteration/deregulation of a single factor can significantly increase the risk of 
carcinogenesis. 
 
1.1.2 Colorectal Cancer Stem Cells (CSCs) 
 
According to the traditional model of tumorigenesis, called the stochastic model, every cell 
within the tumor population is able to initiate and propagate tumor development, following 
multiple genetic mutations. However in the last several years evidence was obtained 
supporting the idea that only a small fraction of cells, with stemness characteristics, 
possess the unique property of tumor initiation. This concept has generated a new model 
for carcinogenesis called Cancer Stem Cell (CSC) model (Huang et al., 2008). Indeed, 
CSCs have been isolated from different types of tumor, including colon. In particular the 
existence of colon CSCs was reported for the first time in 2007 by the research groups of 
O’Brien and De Maria (De Maria et al., 2007 and O’Brien et al., 2007) using CD133 
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glycoprotein as marker. Both research groups, independently, observed that only a small 
population of cancer cells, positive for CD133 expression, was able to initiate tumor 
growth during serial transplantations in immunodeficient mice recapitulating the original 
tumor, while negative cells were not able to do so. CSCs show similar properties with 
normal SCs such as slow cycling, high expression of anti-apoptotic proteins and ATP-
binding cassette (ABC) transporters, which could explain the failure of canonic anticancer 
treatments which, on the contrary, target differentiated and proliferating cells (Scopelliti et 
al., 2009). Based on these features, CSCs could play a key role in cancer recurrence after 
radio/chemotherapy, due to the fact that they are resistant to standard treatments and 
possess cancer-initiating potential.  
Despite initial description of CD133 as a potential CSC marker, CD133 expression is not 
restricted to CSCs only, but also expressed in differentiated colonic epithelium, with 0,4-
2,1% expression in healthy tissue versus 8.9-15.9% in cancer (Catalano et al., 2012). For 
this reason, several additional molecules have been proposed as putative colon CSCs 
markers including CD44, CD24, CD166, Lgr5 and ALDH-1 (Vaiopoulos et al., 2012). A 
combination of these markers is likely more suitable for the identification and isolation of 
true colon CSCs (Haraguchi et al., 2008). 
 
1.1.3 Colorectal CSC markers: CD133 and Lgr5 
 
Several studies reported that the expression of CSC markers in CRC has prognostic 
significance (Coco et al., 2012 and Zhang et al., 2012), consequently targeting these cells 
is suggested to enhance the success of cancer therapy. As mentioned above, the first 
putative colon CSC marker reported was CD133 (De Maria et al., 2007 and O’Brien et al., 
2007). It is a pentaspan transmembrane glycoprotein implicated in the organization of 
plasma membrane, with two large N-glycosylated extracellular loops, two small 
intracellular domains and a cytoplasmic C-terminal domain as show in figure 2A (Yin et 
al., 1997). Although its function in tumor progression remains still unclear, CD133 could 
play a role in cell polarity through cell-cell and cell-matrix contact (Giebel et al., 2004). In 
fact, CD133 was reported to be localized at the lipid rafts on the cell membrane 
contributing to the activation of signalling cascades (Simons et al., 2000). This 
glycoprotein seems to be involved into stem cell properties maintenance such as the 
balance between symmetric and asymmetric cell division (Bauer et al., 2008). Therefore, 
Pilati et al. suggested that CD133 mRNA levels of circulating tumor cells could have a 
prognostic value in advanced colorectal cancer (Pilati et al., 2012). In particular, they 
analyzed different genes finding out that only the expression levels of CD133 correlate 
with patients’ survival. In fact, the CD133 expression was significantly higher in the liver 
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metastasis in comparison with primary colon cancer and normal tissue. The transcriptional 
level of CD133 was negatively correlated with disease-specific survival indicating its 
predictive power in CRC. 
 
 
 
Figure 2 Structure of CD133 and Lgr5 
(A)The predicted structure of CD133 consists of an 85 amino acid (aa) N-terminal extracellular domain, five 
transmembrane domains (TM) with two extracellular loops (EX) of 255 aa and 290 aa, two 30 aa intracellular 
domains, and a 50 aa cytoplasmatic tail. Eight N-linked glycosylation sites are the binding sites of antibodies 
(AC133 and AC141). Taken from (Catalano et al., 2012). (B) Lgr5 is predicted to encode a 7-transmembrane 
protein with a large extracellular domain for ligand binding and a short cytoplasmic tail for coupling to G-
proteins. Taken from (Barker et al., 2008). 
 
Among all the proposed putative CSC markers Leucine-rich repeat-containing G-protein 
coupled receptor 5 (Lgr5), a Wnt target gene, is considered one of the most promising 
(Barker et al., 2008). Its structure consists of seven transmembrane loops, a large 
extracellular domain for ligand binding and a short cytoplasmic tail for coupling to G-
proteins as show in figure 2B (Barker et al., 2008). For a long time Lgr5 was considered 
as an orphan receptor, but in 2011 de Lau et al. identified for the first time R-spondin as 
ligand for Lgr5 (de Lau et al., 2011). Although its specific function is still under debate, the 
expression of Lgr5 is exclusively restricted to the base of the intestinal crypt, where the 
intestinal SC niche is located (Barker et al., 2007). Additionally, due to the fact that Lgr5 is 
a target of the Wnt pathway, this protein is probably involved in maintenance of the correct 
SC niche environment. 
First evidence that Lgr5 is a specific CSC marker and that it can be used to isolate CSCs 
from colorectal cancer, was reported in 2012 by Kemper et al. They demonstrated that 
three new monoclonal antibodies against Lgr5 can identify the CSC population in human 
colorectal cancer. In fact, the CRC cells selected for high expression levels of Lgr5 were 
more clonogenic and tumorigenic than CRC cells which showed low Lgr5 expression 
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levels. Kemper and colleagues (Kemper at al., 2012) also observed that the 
overexpression of Lgr5 induced a higher clonogenic growth in vitro, indicating that this 
protein is a new functional marker for colorectal CSCs identification. 
 
1.2 Apoptosis  
 
Apoptotic cell death is a physiological process genetically controlled that maintains the 
body homeostasis eliminating damaged or stressed cells in a way that is expected to 
cause the slightest damage and no inflammation (Garg et al., 2010). The canonic 
therapeutic strategies for tumor treatment such as chemotherapy, radiotherapy and new 
protein drugs all operate via  inducing programmed cell death in cancer cells. Two forms 
of apoptosis have been found: the intrinsic and the extrinsic apoptotic pathways (Figure 
3). The intrinsic pathway, also known as mitochondrial pathway, is activated in response 
to cellular stress including DNA damage, oxidative stress, chemotherapy and 
radiotherapy. It is mainly regulated by the balance between the members of the Bcl 
superfamily which consists of pro-apoptotic proteins as Bak and Bax; and the anti-
apoptotic members like Bcl-2, Bcl-XL and Mcl-1. A crucial sensor of cellular damage is the 
tumor suppressor protein p53 which can regulate the expression of the genes of pro-
apoptotic proteins such as Puma, Noxa, Bax and Apaf-1 inducing cell death via the 
intrinsic pathway (Vousden et al., 2002). In particular, the pro-apoptotic proteins induce 
the permeabilization of the mitochondrial outer membrane and consequently the release 
into the cytosol of co-factors of apoptosis like cytochrome c and Smac/Diablo. The 
cytochrome c and dATP induce Apaf-1 and caspase 9 to assemble the apoptosome in 
which caspase 9 is activated and in turn can activate downstream effectors such as 
caspase 3, 6, 7 to further catalyze the effector phase of apoptosis (Sprick et al., 2000 and 
Ashkenazi et al., 2008). SMAC/Diablo can indirectly promote apoptosis by inhibition of the 
members of the IAPs (inhibitor of apoptosis) family such as XIAP, cIAP1 and cIAP2. The 
IAPs are in fact able to ubiquitinate the initiator caspase 9 and the effectors caspase 3 
and 7, thereby leading to proteasomal degradation of these critical mediators of apoptosis 
and thus suppress cell death (Falschlehner et al., 2007).  
The extrinsic apoptosis pathway is activated by binding of a death ligands to 
transmembrane receptors called Death Receptors (DRs) that transduce a signal from 
outside into the cell. The interaction between ligands and DRs induces their 
oligomerization that is crucial for the recruitment of the adaptor protein Fas-associated 
death domain (FADD) to the intracellular death domains (DD) of these receptors. FADD in 
turn recruits the pro-caspases 8 and 10 forming the death-inducing signalling complex 
(DISC). At the DISC through an auto-catalytic cleavage caspases 8 and 10 are activated 
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and in turn can directly cleave caspase 3 which itself cleavages other caspases and 
various critical cellular substrates, foremost the Caspase activated DNAse Inhibitor (ICAD)  
leading to irreversible DNA cleavage and subsequent cell death  (Sprick  et al., 2000 and 
Kruyt et al., 2008).  
 
 
 
Figure 3 Intrinsic and Extrinsic pathways of apoptosis 
The extrinsic pathway is triggered by the binding of apoptosis-inducing ligands to pro-apoptotic receptors 
(TRAIL-R1 and TRAIL-R2) resulting in oligomerization of the receptors. The death-inducing signaling complex 
(DISC) is composed of the Fas-associated death domain (FADD), which binds to the death domain (DD) of 
the receptor and recruits the pro-caspases 8 and 10 undergoing auto-activation by proteolytic cleavage 
(caspases 8 and 10). The initiator caspases 8 and 10 activate the downstream effector caspases 3 and 7, 
which execute apoptosis in the cells. The intrinsic pathway is triggered by cellular stress, such as DNA 
damage or by radiotherapy and chemotherapy, resulting in a p53-dependent upregulation of pro-apoptotic 
proteins, like Bax and Bak. These proteins induce the permeabilization of mitochondrions resulting in a 
release of cytochrome c and Smac/DIABLO into the cytosol. The apoptosome is composed of Apaf-1, 
cytochrome c and caspase 9, exhibiting the activation of the effector caspases 3 and 7. Smac/DIABLO also 
activates apoptosis indirectly by inhibiting the subfamily of inhibitors of apoptosis (IAPs). The cross-talk 
between the extrinsic and the intrinsic pathway is performed by the pro-apoptotic protein Bid, which can be 
cleaved and activated by caspase 8. This protein induces apoptosis by inhibiting the anti-apoptotic proteins 
Bcl-2 and Bcl-XL and by activating the pro-apoptotic proteins Bax and Bak. Taken from (Carlo-Stella et al., 
2007). 
 
 
Based on in vitro studies, cells have been classified in two categories of differing in the 
pathway used for apoptosis induction. In type 1 cells the cell death is triggered via the 
extrinsic pathway upon activation of the DRs. While in the type 2 cells, the induction of 
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caspase 3 activation by DISC is insufficient to trigger apoptosis and they need an 
additional amplification step via the mitochondrial pathway (Ozören and El-Deiry, 2002). 
The link between the extrinsic and the intrinsic pathways is represented by the pro-
apoptotic protein Bid, a member of the Bcl2 family. Bid can be cleaved by active caspase 
8 into a truncated form (tBid). Cleaved Bid translocates to the mitochondria and interacts 
with Bax and Bak inducing their oligomerization and the release of Cytocrome c and 
SMAC/Diablo and the consequent activation of the downstream effectors caspases (Kruyt 
et al., 2008). 
 
1.3 TNF-Related apoptosis inducing ligand: TRAIL 
 
TNF-Related apoptosis inducing ligand (TRAIL), also known as Apo2L, is a member of the 
TNF superfamily. The tumor necrosis factor (TNF) was the first death ligand discovered in 
1975 and used for anticancer treatment (Carswell et al., 1975). Although TNF showed cell 
death induction in some cancer types, it soon became clear that its major function was in 
the pro-inflammatory process and this activity could explain the high toxicity observed 
after systemic administration of TNF (Tracey et al., 1987; Tracey et al., 1988; Roberts et 
al., 2011). Afterwards, the death receptor (DR) FAS/Apo1 (CD95) was proposed as 
anticancer target, based on the finding that two antibodies targeting this receptor induced 
apoptosis in various cancer cell lines (Trauth et al., 1989 and Itoh et al., 1991). 
Unfortunately, similar to the TNF outcomes, tumor treatment with systemic administration 
of CD95 agonistic antibodies caused fulminant and lethal hepatotoxicity (Ogasawara et 
al., 1993). Few years later TRAIL was identified based on its sequence homology to the 
others members TNF and CD95 (Wiley  et al., 1995 and Pitti et al., 1996). In this case, in 
contrast to TNF and CD95 results, TRAIL showed antitumoral activity in vivo without 
inducing toxicity during systemic treatment (Ashkenazi et al., 1999 and Walczak et al., 
1999). This new member apparently possesses the unique ability to induce apoptosis 
selectivity in cancer cells and not in normal cells.  
TRAIL is a homotrimeric molecule which can bind five types of receptors: TRAIL-Receptor 
1 (TRAIL-R1) also called Death Receptor 4 (DR4); TRAIL-R2 (DR5); TRAIL-R3 and 
TRAIL-R4 also named respectively decoy receptor 1 and 2 (DcR1 and DcR2) and a 
soluble molecule osteoprotegerin (OPG) (Lemke et al., 2014). Although all the four trans-
membrane receptors bind TRAIL, the apoptotic process can be induced only via TRAIL-
R1 and TRAIL-R2 due to the fact that DcR1 lacks the intracellular domain and DcR2 
contains only a truncated one (Wang et al., 2003). The interaction between TRAIL and the 
extracellular domains of TRAIL-R1 or TRAIL-R2 induces receptor oligomerization that is 
crucial for the recruitment of the adaptor protein Fas-associated death domain (FADD) to 
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the intracellular death domains, the formation of the DISC complex and the caspases 
activation (Sprick  et al., 2000 and Kruyt et al., 2008).  
 
1.3.1 TRAIL: combination therapy for tumor treatment 
 
Tumors are heterogeneous populations of cells with a genetic and epigenetic unstable 
background (Meacham et al., 2014). For this reason cancer cells show different 
responses to TRAIL. In some case tumor cells are intrinsically resistant to TRAIL induced 
apoptosis, but they can also acquire resistance to TRAIL during tumor progression 
(Stuckey et al., 2013). However, many chemotherapeutic agents commonly used in 
cancer therapy have shown a synergistic effect with TRAIL, such as gemcitabine, 
doxorubicine, 5-Fluro Uracil (5-FU), cisplatin and irinotecan (reviewed by Newsom-Davis 
et al., 2009) and they can overrule the constitutive TRAIL resistance of several cancer cell 
lines (Hellwig et al., 2012). The molecular mechanisms that regulate this sensitization to 
TRAIL are not yet completely elucidated and are dependent on the different mode of 
action of the drugs (Dimberg et al., 2013). Novel drugs used in combination with TRAIL 
are under pre-/clinical evaluation, these so-called Smac mimetics mimic the XIAP (X-
linked inhibitor of apoptosis protein) binding site of SMAC/Diablo, thus blocking XIAP as 
well as cIAP (cellular inhibitor of apoptosis) function and inducing there rapid degradation. 
These small molecules have shown, in a variety of cancer types, a strong sensitization of 
tumor cells to TRAIL activity both in vitro and in vivo (Li et al., 2004; Fakler et al., 2009; 
Lecis et al., 2010). Another promising agent, which displays antitumoral activity alone or in 
combination with TRAIL is bortezomib, a proteasome inhibitor, commonly used to treat 
different kinds of cancers including liver, breast, lung and pancreatic cancer (reviewed by 
de Wilt et al., 2013).  
 
1.3.2 Bortezomib as sensitizer of TRAIL activity 
 
Bortezomib (VELCADE) is a proteasome inhibitor and is currently approved by the Food 
and Drug Administration (FDA) for the treatment of multiple myeloma and mantle cell 
lymphoma (Orlowski et al., 2008 and Raab et al., 2009). In particular, bortezomib can 
reversibly bind the β5 subunit of the 26S proteasome, the major non-lysosomal protein 
degradation complex, causing the inhibition of the chymotrypsin-like proteolytic activity 
(Adams et al., 2003). Due to this inhibition polyubiquitinated proteins are accumulated and 
inefficiently degraded causing cell cycle arrest and the activation of the apoptotic pathway. 
Bortezomib is a potent sensitizer of TRAIL pro-apoptotic activity and the antitumoral effect 
of combined treatment was reported in vitro and in vivo in a broad range of different 
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cancers (reviewed by de Wilt et al., 2013). The sensitization of bortezomib affects TRAIL 
signalling pathway at multiple levels. For example, treatment with bortezomib was 
reported to increase TRAIL-R1 and/or TRAIL-R2 expression in various tumors types, 
resulting in enhanced apoptotic signalling (Koschny et al., 2007 and Liu et al., 2010). 
Another crucial effect of bortezomib activity on TRAIL pathway is the enhancement of 
caspase 8 activation at the DISC complex l (Brooks et al., 2010 and Seki et al., 2010). 
Furthermore, the inhibition of 26S proteasome affects the expression of various target 
genes at the transcriptional level by changing the stability of transcription factors like NF-
kB. The activity of NF-kB is regulated by the repressor protein IkB, which is controlled by 
proteasome degradation. Bortezomib administration prevents IkB degradation, which 
consequently inhibits NF-kB dependent transcription  of several  anti-apoptotic target 
genes like c-FLIP, Bcl-XL and XIAP (Kreuz et al., 2001 and Sayers et al., 2003). As 
reported by Khanbolooki et al, treatments of pancreatic cancer cells with bortezomib as 
well as with a specific NF-kB inhibitor showed downregulation of XIAP and Bcl-XL 
expression and TRAIL sensitization (Khanbolooki et al., 2006). Concerning the Bcl-2 
family, the effect of bortezomib on this group of proteins is not completely clear and it 
seems to be cell-type dependent. Nevertheless, Naumann et al. (Naumann et al., 2011) 
found that treatments with bortezomib stabiles N-terminal and C-terminal fragments of Bid 
following its cleavage by caspase 8. Furthermore, bortezomib can inhibit degradation of 
the C-terminal fragment of cleaved Bid via proteasome leading to enhancement of 
mitochondrial apoptotic pathway. 
The efficacy of combined therapy using bortezomib and TRAIL has been explored in 
several xenograft mice models, e.g. as reported by Wahl et al. (Wahl et al., 2013) in 
hepatocellular carcinoma treatment and in a colorectal cancer xenograft model by 
Siegemund et al. (Siegemund et al., 2012). 
 
1.3.3 Db-scTRAIL fusion proteins targeting colorectal CSCs 
 
The failure of conventional tumor treatments is mainly due to metastasis formation and 
recurrence of cancer even after surgery and a long term period of chemo/radiotherapy. 
Interestingly, both of these processes seem to be caused and regulated by CSCs. The 
hypothesis that only tumor-initiating cells are able to form new tumor in a different site, 
was reported by Dieter et al. and Kreso et al. for CRC (Dieter et al., 2011 and Kreso et al., 
2013). They observed that metastasis derived from a subpopulation of cells, located in the 
primary tumor, which shows specific CSCs properties such as chemotherapy resistance, 
quiescent status and self-renewal ability. Furthermore, traditional tumor treatments have 
been generated to target and eradicate proliferating cells, but the small fraction of CSCs 
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within the tumor is, by and large, not affected and thus may cause cancer recurrence after 
months or years of apparent remission (Scopelliti et al., 2009).  
This complex scenario underlines the need to develop new therapeutic agents targeting 
specifically CSCs that, potentially also in combination with canonic chemotherapy, could 
be significantly more efficient in prevention of metastasis formation and tumor regrowth. A 
new, promising approach to effectively attack malignant cells is based on the proapoptotic 
ligand TRAIL because of its presumed tumor selective activity and its high tolerability 
upon systemic administrations in humans (Yee et al., 2007 and Wainberg et al., 2013). 
However, several clinical trials testing the conventional recombinant TRAIL revealed that 
the use of this protein is largely ineffective to achieve significant therapeutic effects 
(Herbst et al., 2010 and Soria et al., 2010). These negative results are mainly due to the 
low in vivo bioactivity of the TRAIL molecules used and their short plasma half-life. In 
order to overcome these limitations an alternative approach, based on TRAIL fusion 
proteins targeting tumor markers, was investigated. First, fusion of three TRAIL domains 
into one polypeptide chain, through short peptide linkers, results in a single chain 
derivative of TRAIL (sc-TRAIL) which showed higher stability and antitumoral activity 
(Schneider et al., 2010). Furthermore, as reported by Siegemund et al. (Siegemund et al., 
2012), the dimerization of single chain TRAIL (scTRAIL) proteins and an EGFR targeting 
scFv  can be combined to obtain bifunctional fusion proteins, a Diabody-scTRAIL. These 
constructs maintain the ability to bind TRAIL receptors and simultaneously to target 
specific cancer antigen, In this example EGFR,  resulting in enhancement of apoptotic 
induction both in vitro and in vivo.  
 
1.4 Mesenchymal Stem Cells 
 
An additional strategy to target and treat efficiently not only primary tumors but also the 
metastatic sites is the use of stem cell as delivery system for in situ expression of 
therapeutics. Mesenchymal stem cells (MSCs) are adult stem cells, which are currently 
exploited for different cellular therapies in clinical applications. The discovery of MSCs 
was reported for the first time in 1960s by Friedenstein et al. (Friedenstein et al., 1966 and 
Friedenstein et al., 1968) in the stromal compartment of bone marrow (BM) and they were 
described as clonal fibroblastic stromal cells that formed adherent colonies in culture and 
had robust osteogenic potential. The term “mesenchymal stem cells“ (MSCs) was defined 
for the first time by Caplan et al. in 1991 (Caplan et al., 1991) and their potential to multi 
lineage differentiation into bone, cartilage and fat cells was described in 1999 by Pittenger 
and colleagues.  
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In 2006 the International Society of Cellular Therapy (ISCT) has established three minimal 
criteria for defining MSCs. First, MSCs must show in vitro adherence to plastic in standard 
culture conditions; second, MSCs must express specific surface antigen such as CD9, 
CD71, CD105 and lack expression of other markers like CD34, CD14 and CD11b. 
According to the third criteria, MSCs must have the ability to differentiate into osteoblasts, 
adipocytes and chondroblasts in vitro (Dominici et al., 2006). This definition and 
characterization of MSCs still relies only on in vitro culture cell and consequently the 
localization and the in vivo distribution of MSCs are much less known (Hernanda et al., 
2014). Nevertheless, in the last years MSCs were isolated from a variety of different 
organs/tissues such as bone marrow, kidney, adipose tissue, umbilical cord, brain, liver 
and lung (Zuk et al., 2001; da Silva Meirelles et al., 2006; Choi et al., 2014). The highest 
level of lineage plasticity has been imputed to bone marrow derived MSCs, which have 
been described to generate virtually all cell types following implantation into early 
blastocysts (Jiang et al., 2002). In spite of the fact that MSCs reside in the bone marrow in 
small number (0.001-0.01% of nucleated cells) (Kawada et al., 2004), they are easy to 
handle and expand in vitro to yield a sufficient number of cells for clinical applications. The 
most abundant source of MSCs in the human body is the adipose tissue obtained from 
subcutaneous tissue using simple and non-invasive techniques (Kern et al., 2006). Due to 
their accessibility and easy expansion protocols, MSCs have been recognized as 
promising candidates to set up new cellular therapies in regenerative medicine but also for 
treatment of various other diseases. 
 
1.4.1 MSCs properties 
 
In addition to the ease isolation from many different tissues and the convenient expansion 
in vitro, MSCs possess unique biological characteristics that make them an attractive 
therapeutic agent for treatment of a wide range of different pathologies. 
 
Multi lineage differentiation potential  
 
Giving the fact that MSCs belong to the mesoderm lineage they can differentiate in 
various cell types according to their own original lineage and to the tissue in which they 
reside. Their ability to generate bone, cartilage, and adipose tissues has been well 
documented both in vitro (Muraglia et al., 2000) and in vivo (Aslan et al., 2006). However 
the differentiation potential of MSCs appears exceptional. In fact, further studies reported 
that, using cytokine induction and/or gene introduction, MSC differentiate in vitro into cells 
of other lineages including endodermal (hepatocytes and insulin-producing cells) and 
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ectodermal lineages (neuronal, peripheral glial and epidermal cells) (Prockop et al., 1997; 
Dezawa et al., 2001; Oyagi et al., 2006; Wu et al., 2006; Karnieli et al., 2007; Dezawa et 
al., 2004). However the frequency of these differentiation events is generally very low and 
is considered to correspond to a small, potentially an as yet undefined subpopulation of 
MSCs. While the capacity to form the three distinct cell types: osteoblasts, chrondrocytes 
and adipocytes, remains the only reliable functional criterion to define MSCs. 
 
Immunosuppressive properties 
 
MSCs are considered immune privileged cells potentially “ignored” by the immune system. 
This can be explained by the fact that these cells express low levels of major 
histocompatibility (MHC) class I surface markers and are negative for MHC class II 
expression. Furthermore, they lack the expression of co-stimulatory molecules such as 
CD40, CD80 and CD86. Despite the low levels of MHC class I antigens a potential 
activation of T cells is conceivable, however, in the absence of co-stimulatory molecules 
the mandatory secondary signals for T cell activation are lacking, thus leaving the T cells 
anergic (Javazon et al., 2004). Furthermore, despite reduced levels of MHC class I 
antigens, these are sufficient toprotect MSCs from natural killer  (NK) cell-mediated 
cytotoxicity, because cells that lack MHC class I antigens are targeted and destroyed by 
NKs (Moretta et al., 2001). In addition, MSCs can secrete a range of immunomodulators, 
such as nitric oxide (NO), prostaglandin (PGE2), indoleamine 2,3-dioxygenase (IDO), 
interleukin (IL)-6, IL-10, and HLA-G. These soluble factors are known to negatively 
modulate the function of various immune cells. In addition, through cell-cell contact and 
the production of soluble factors, MSCs induce an immunosuppressive environment by 
generating regulatory T cells (Tregs). The ability of MSCs to induce Tregs has been 
observed both in vitro (Di Ianni et al., 2008 and Ye et al., 2008) and in vivo in various 
models (Zappia et al., 2005; Nemeth et al., 2010; Madec et al., 2010). 
 
Tumor homing of MSCs 
 
One of the most important and unique properties of MSCs is their ability to migrate to site 
of wounds, chronic inflammation and tissue damage as well as to the tumor 
microenvironment (Spaeth et al., 2008). The first evidence of MSCs’ tumor tropism was 
reported in 1999 by Maestroni at al., showing also that bone marrow derived MSCs 
release some soluble factors that inhibit lung carcinoma and melanoma growth in mice. In 
the past decades the homing potential of MSCs was discovered in almost all tested 
cancer cell lines: colon cancer (Menon et al., 2007), breast cancer (Kidd et al., 2009), 
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melanoma (Studeny et al., 2002), pancreatic cancer (Kidd et al., 2010), ovaric cancer 
(Kidd et al., 2009), lung cancer (Loebinger et al., 2009), Kaposis’s sarcoma (Khakoo et al., 
2006) and malignant glioma (Sasportas et al., 2009). The mechanism by which MSCs 
migrate across endothelium and home to the tumor site is not yet fully understood, 
however it seems to be dependent upon biological properties of the tumor micro-
environment (Roisin et al., 2010). Since a tumor can be considered a “wound“, its 
microenvironment resembles a site of chronic inflammation with high concentrations of 
inflammatory chemokines and growth factors. These factors may be responsible for 
integration of MSCs into the tumor stroma. Extensive studies have shown that MSCs can 
be attracted by different cytokine/receptors pairs including SDF-1/CXCR4, SCF/c-Kit, 
HGF/c-Met, VEGF/VEGFR, PDGF/PDGFR, MCP-1/CCR2, and HMGB1/RAGE (reviewed 
by Momin et al., 2010). MSCs express a variety of chemokine receptors: CCR1, CCR2, 
CCR4, CCR6, CCR7, CCR8, CCR9, CCR10, XCR, CXCR1, CXCR2, CXCR3, CXCR4, 
CXCR5, CXCR6 and CX3CR (Ringe et al., 2007). The production of their respective 
ligands is a shared characteristic of tumor tissue and thus these receptors may likely play 
a role in MSCs migration and tumor homing. Other influential signalling pathways have 
been elucidated and include PI3K signalling (Kendall et al., 2008), urokinase-type 
plasminogen activator (uPA)-uPA receptor (uPAR) (Vallabhaneni et al., 2011) and matrix 
metallo-proteinase 1 (MMP1)-proteinase-activated receptor 1 (PAR1) (Gutova et al., 
2008). Two recent studies show that human MSCs migrate in vitro and in vivo toward 
hepatocellular carcinoma. In one case the chemotaxis is reoriented due to the chemokine 
CCL15, secreted by the tumor cells, that binds the CCR1 receptor on MSCs (Gao et al., 
2016). While in the second one, the monocyte chemoattractant protein-1(MCP-1) 
expressed by lung cancer cells, interacts with the CCR2 receptor expressed on the 
surface of human MSCs (Yan et al., 2016).  
Additional receptors involved in MSCs migration are Toll-like Receptors (TLR). In 
particular TLRs1-6 have been identified in primary human MSCs and have been reported 
that TLR stimulation enhanced the migratory ability of MSCs (Tomchuck et al., 2008). 
The migration towards a tumor site in vivo is influenced not only by the tumor 
microenvironment but also by the nature of MSCs such as: heterogeneity of the 
population, culture conditions of in vitro MSC expansion and the expression of migratory 
factors. Besides targeting the primary tumor mass, MSCs have been shown to track tumor 
metastasis sites (Sasportas et al., 2009). Two recent studies, in fact, reported that MSC 
administration results in strong recruitment within colon cancer lung metastasis (Knoop et 
al., 2015) and breast cancer lung metastasis (Liu et al., 2015). 
Furthermore many tumor microenvironments exhibit hypoxia that results in expression of 
proangiogenic molecules. The hypoxia-induced transcription factor HIF-1α activates the 
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transcription of genes, including VEGF, macrophage migration inhibitor factor, tumor 
necrosis factors, and numerous pro-inflammatory cytokines (Winner et al., 2007), inducing 
the production of chemokines, such as MCP-1, involved in migration of MSCs toward 
tumors (Dwyer et al., 2007). These cells are relatively resistant to hypoxic conditions due 
to anaerobic adenosine triphosphate production (Mylotte et al., 2008) which should give 
these cells a competitive advantage in the tumor microenvironment.  
 
1.4.2 MSCs and clinical applications  
 
Therapeutic use of MSCs is a promising strategy to treat a large number of different 
diseases. Their feasibility of isolation from different adult tissues and expansion in culture, 
the capacity to avoid immune rejection and their homing ability are some of the properties 
that make MSCs a great resource for cell based therapy. One of the first clinical 
applications of MSCs was in the tissue regeneration field, where they can be used as an 
alternative to donated organs by offering a renewable cell source for replacement of 
degenerated tissue. In 1995 Lazarus et al., reported for the first time that MSCs can be 
safely applied in an oncological indication, too: 15 patients with hematological 
malignancies were infused with autologous cultured MSCs, resulting in complete 
remissions (Lazarus et al., 1995). Few years later MSCs were successfully used by 
Horwitz et al. 1999, to treat children affected by osteogenesis imperfecta. The allogeneic 
hematopoietic stem cells transplantation and the transplanted bone marrow cells 
engrafted and generated functional osteoblasts leading to improvement in bone structure 
and function (Horwitz et al. 1999).   
In cardiovascular diseases MSCs have been used to treat acute and chronic myocardial 
infarction patients, with significant improvements in heart functions (Chen et al., 2006 and 
Zeinaloo et al., 2011). In addition to autologous MSCs, the efficacy of allogeneic MSCs 
has also been reported. Allogeneic MSCs were well tolerated with a significant increase in 
left ventricular ejection fraction and lower incidences of arrhythmia and chest pain (Ichim 
et al., 2008). 
Based on their ability to modulate immune responses, MSCs have also been proposed as 
a treatment for autoimmune diseases. Thus, the therapeutic role of MSCs was 
investigated in patients with Crohn’s disease, a chronic inflammatory disorder in which the 
immune system attacks the gastrointestinal tract. The patients were given intralesional 
treatments of MSCs mixed with fibrin glue, showing signs of significant repair 8 weeks 
after treatment (Garcia-Olmo et al., 2009). The effect of MSCs has also been documented 
in systemic lupus erythematosus (SLE), an autoimmune inflammatory disease with 
multiorgan involvement including the kidney, brain, lung and hematopoietic systems 
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(Wang et al., 2013). A study published by Sun and colleagues suggested that MSCs 
derived from SLE patients show functional abnormalities (Sun et al., 2007) and, thus, 
allogeneic MSC transplantation may be more effective, as compared to autologous MSCs. 
Clinical support for this reasoning was obtained in a pilot study showing that allogeneic 
MSC transplantation improved serological markers and stabilized renal functions in 
refractory SLE patients (Liang et al., 2010). In addition, clinical studies using MSCs 
revealed the prevention of graft-versus-host disease, which is one of the complications 
and risks during autologous or allogeneic hematopoietic stem cell transplantation (Figure 
4) (Lin et al., 2011). 
Furthermore, MSCs have been used to treat liver diseases due to their regenerative 
potential and immunomodulatory properties. In a phase I to II clinical trial, eight patients 
with end-stage liver diseases received autologous MSCs that were well tolerated and 
improved liver functions, demonstrating that MSC therapy is safe, feasible, and applicable 
in end-stage liver disease (Kharaziha et al., 2009). 
 
 
 
 
Figure 4 Multiple modes of action attributed to MSCs 
The potential utility of MSCs resides in their multifunctional properties. They modulate the immune system, 
enhance engraftment of hematopoietic stem cells, promote tissue healing and contribute to structures such as 
bone, cartilage, and fat. As culture-expanded cells, they may provide critical trophic support for normal tissue 
maintenance and protection and recovery from tissue injury. In addition, MSCs can be exploit as cell-based 
gene delivery system for the expression of antitumoral agents. Taken from (Viswanathan et al., 2014). 
 
1.4.3 MSCs as drug delivery system 
 
The lack of selectivity, often resulting in considerable loss of healthy tissue, is one of the 
main limitations of conventional tumor therapies. Most researchers agree that cell based 
therapy as targeted delivery system has a promising future, especially for cancer 
treatments, in order to proactively focus on tumor tissue and to efficiently attack malignant 
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cells. An encouraging method is based on the use of MSCs as cellular carrier vehicle for 
the expression of antitumoral peptide/protein based reagents. These cells, in fact, will not 
only provide a delivery system that is immune privileged (Ye et al., 2008) but they are 
expected to home to the cancer site, due to their tumor tropism (Studeny et al., 2002), and 
here serve as a delivery platform to stably express therapeutic proteins, increasing their 
concentration at the target site. Consequently, a constant in situ production can 
circumvent the short half-lives that all low molecular weight peptide and most non-
antibody based protein reagents exhibit. Moreover, the presumed local expression of the 
therapeutic in the tumor microenvironment would avoid broad systemic action causing 
potential off target actions, so-called unwanted side effects. Support for the feasibility of 
the MSC drug carrier concept was obtained in several preclinical studies. An early 
application of MSCs was the transduction with the Interferon β (IFN-β) gene which shows 
a wide range of biological activities like anti-proliferative (Johns et al., 1992) and pro-
apoptotic (Chawla-Sarkar et al., 2001) effects. However, its in vivo therapeutic efficacy 
has been limited due to toxicity associated with systemic administration. Studeny et al. 
reported (Studeny et al., 2002) that i.v. administration of MSCs, engineered to express 
IFN- β (IFN-β-MSCs), significantly prolonged the survival of animals with established 
metastases of either breast carcinoma or melanoma tumor in the lung. Toxic effects 
associated with IFN-β were reduced by the delivery of MSCs expressing IFN-β to tumors. 
In addition Nakamizo et al. (Nakamizo et al., 2005) have observed that IFN-β-MSCs show 
tropism for human gliomas after either intravascular or local delivery with a significant 
extension of the survival of animals with established intracranial gliomas. 
Others candidates as therapeutic agents secreted by MSCs are the interleukins (ILs), 
regulators of inflammatory and immune responses. ILs can be used to improve the anti-
cancer immune surveillance by activating cytotoxic lymphocytes, natural killer cells, and 
producing IFN-γ (Studeny et al., 2002). MSCs genetically modified with IL-12, when mixed 
with melanoma cells, significantly delayed tumor growth in a dose-dependent manner 
(Shrayer et al., 2002). Likewise, when IL2-expressing MSCs are injected in the vicinity of 
pre-established melanoma in mice tumor growth was inhibited (Stagg et al., 2004). 
Furthermore, Chen et al. (Chen et al., 2012) showed that the administration of MSCs 
transduced with IL-12 suppress metastasis and increase tumor cell apoptosis in mice 
bearing melanoma, lung cancer and hepatoma. 
In addition, the activation of systemically delivered, inactive prodrugs that are converted 
into biologically active cytotoxic agents by genetically modified MSCs homing to the tumor 
is an alternative concept. The first example of this strategy was the application of cytosine 
deaminase (CD), which can convert the nontoxic prodrug 5-fluorocytosine to the 
antitumoral agent 5-fluorouracil, that can diffuse out of the producer MSCs into 
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surrounding cells and is selectively toxic only to rapidly proliferating cells (Chang et al., 
2010). Another prodrug system that was evaluated is the Herpes simplex virus-Thymidine 
kinase (HSV-TK) in combination with ganciclovir (GCV). This latter is a nontoxic purine 
analogue and is phosphorylated by the enzyme HSV-TK and further by endogenous 
kinases. The final phosphorylated form, GCV-triphosphate, inhibits DNA synthesis and 
induces cell death via apoptosis (Moolten et al., 1990). In particular, Song et al. have 
shown that MSCs transduced with HSV-TK significantly inhibit the growth of 
subcutaneous prostate cancer xenografts as well as metastatic tumor in the presence of 
prodrug GCV (Chao et al., 2011).  
Furthermore MSCs can be engineered to express pro-apoptotic proteins like TRAIL which 
has the ability to induce apoptosis selectively in cancer cells and leaving normal cells 
intact (Walczak et al., 2000). The therapeutic efficacy of TRAIL expressed by transduced 
MSCs for tumor treatment has been shown in different cell lines or mouse models such as 
colorectal carcinoma (Mueller et al., 2011), gliomas (Ehtesham et al., 2002), lung, breast, 
and cervical cancer  (Loebinger et al., 2009) (Figure 5).  
 
 
 
Figure 5 Using stem cells to promote tumor cell death 
SCs can be modified in various ways to generate antitumour capabilities. (A) SCs can be engineered to 
secrete therapeutic proteins that function directly on tumor cells or indirectly on cells of the tumor 
microenvironment. For example, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), epidermal 
growth factor (EGF) agonists or interferons (IFNα or IFNβ) can be secreted to function on death receptor 4 
(DR4) and DR5, EGF receptor (EGFR) or IFN receptors (IFNRs), respectively. (B) SCs can be engineered to 
express a suicide gene encoding an enzyme (such as cytosine deaminase (CD), carboxylesterase (CE) or 
herpes simplex virus thymidine kinase (HSV-tk)) that converts a prodrug into a toxin. This induces suicide of 
the SCs, and cancer cells are killed by the bystander effect, a phenomenon that describes the movement of 
toxin from the SCs to adjacent cancer cells via a paracrine mechanism or gap junctions. The distant bystander 
effect describes the recruitment of host immune cells in response to death or inflammatory signals released 
from dying cells. Adapted from (Stuckey and Shah, 2014). 
 
A combined approach was also investigated in stem cells based gene therapy, in order to 
synergize with the delivered agent or to sensitize resistant populations. For example, 
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delivery of TRAIL mediated by stem cells was combined with various agents such as 
PI3K-mTOR inhibitor, histone deacetylases (HDACs) inhibitors, short hairpin RNA 
(shRNA), micro RNA inhibitors as well as bortezomib and cisplatin, resulting in enhanced 
pro-apoptotic TRAIL mediated activity (reviewed by Stuckey et al., 2013). 
 
1.4.4 MSCs: pro-tumorigenic or anti-tumorigenic? 
 
The tumor microenvironment is a complex structure composed of malignant tumor cells, 
also known as parenchyma, and a stroma compartment. The tumor stroma contains 
different kind of cells including cancer-associated fibroblasts (CAFs) (Levin 1912), 
endothelial cells (Greenblatt et al., 1968 and Duda et al., 2006), immune cells (Woods et 
al., 1997 and Lyden et al., 2001), adipocytes (Andarawewa et al., 2005) and various types 
of extracellular matrix (ECM) proteins (Levin 1913). These stroma elements play a crucial 
role in tumor survival, structural support and vascularization. Due to their tumor homing 
ability, MSCs move to tumor site and incorporate into the tumor stroma compartment, 
interacting with each other and with cancer cells (Kidd et al., 2009). The exact role of 
MSCs in the tumor stroma and consequently their effects on tumor progression or tumor 
inhibition is still controversial. There are conflicting findings in studies concerning the use 
of MSCs for cell based therapy. In fact, several publications have reported pro-
tumorigenic effects of MSCs through different processes such as: promotion of 
angiogenesis and metastasis formation, suppression of the organism’s immune response 
against tumor cells, induction of epithelial-mesenchymal transition (EMT) and transition to 
tumor associated fibroblasts (reviewed by Klopp et al., 2011). In contrast to these 
potentially tumor promoting properties of MSCs, several other studies have demonstrated 
that these cells can reduce or prevent tumor growth. These anti-tumoral effects are 
mediated by different ways including inhibition of signalling pathways involved in cell 
proliferation process like AKT, PI3K and Wnt, downregulation of XIAP (X-linked inhibitor of 
apoptosis protein) and suppression of angiogenesis (Khakoo  et al., 2006; Qiao et al., 
2008; Otsu et al., 2009). 
The reasons for these reported discrepancies are still unknown, but the dual role of MSCs 
in support or suppression of tumorigenesis may depend on many factors. The timing of 
MSCs administration seems to be critical to determinate the final effect on tumor growth. 
In many studies, antitumoral effects were observed when MSCs were injected into 
established tumors and when direct contact of MSCs and tumor was avoided using gelatin 
matrix or intravenous administration of MSCs during tumor initiation (Ohlsson et al., 2003). 
By contrast, in several publications tumor growth was promoted when MSCs and tumor 
cells were injected simultaneously (Djouad et al., 2003 and Karnoub et al., 2007). The 
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heterogeneity of MSCs, furthermore, is probably a critical point as reported by the group 
of Waterman. In these studies MSCs, which express several TLRs (Toll-like receptors), 
were separated into two homogenous phenotypes, called MSC1 and MSC2, according to 
the different downstream TLRs stimulation. The researchers reported that MSC1 exhibited 
a pro-inflammatory nature, whereas MSC2 an immunosuppressive one (Waterman et al., 
2010) and in a cancer model MSC1 treatment reduced primary tumor growth and 
metastasis, while administration of MSC2 resulted in increase of tumorigenesis and 
metastasis formation (Waterman et al., 2012). Additionally, the dose of MSC 
administration and the conditions of their expansion ex vivo are variable factors and may 
contribute to the conflicting results.   
Although the impact of MSCs on tumor progression is still unclear, putative tumor-
promoting effects of MSCs can be overcome by manipulating their gene expression 
pattern. For example, MSCs could be engineered to express a suicide gene. With this 
system, after migration into the tumor and the local expression of antitumor protein, MSCs 
can be targeted by an agent, like gancyclovir, which induces a selective elimination of the 
exogenously delivered MSCs. 
 
1.4.5 Stem cell delivery of TRAIL 
 
Over the past decades many recombinant versions of TRAIL have been generated to 
increase its antitumoral activity (Stuckey and Shah 2013), because of very limited clinical 
efficacy (Herbst et al., 2010 and Soria et al., 2010). This recombinant soluble form of 
TRAIL shows in vivo a short half-life of around 30 minutes (Kelley et al., 2001). This is for 
most due to dissociation of the homotrimer and rapid kidney clearance (Duiker et al., 
2012). Although a lot of different approaches have been investigated to improve the 
stability and pharmacokinetics of a recombinant protein, like addition of leucine and 
isoleucine zipper (LZ-TRAIL Walczak et al., 1999 or iz-TRAIL Ganten et al., 2006) or the 
addition of human serum albumin (Muller et al., 2010), the serum half-life and the specific 
delivery site still remain a major hurdle of this therapeutic strategy. These problems can 
be overcome using cell base gene therapy to express and delivery recombinant proteins 
directly to their site of action, with an increase of their concentration at the target side and 
a simultaneous reduction of potential side effects. Many types of adult stem cells have 
been engineered to secrete soluble form of TRAIL and have been transplanted into mice 
to treat different kinds of tumors as described in Table 1.   
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Table 1 Stem cell delivery of TRAIL for cancer therapy 
Abbreviations: UCB-MSCs, Umbilical cord blood-derived mesenchymal stem cells; BM-MSCs, Bone marrow-
derived mesenchymal stem cells; A-MSCs, Adipose-derived mesenchymal stem cells; NSCs, Neural stem 
cells; NPCs, Neural progenitor cells; sECM, synthetic extracellular matrix; EGFR, Epidermal growth factor 
receptor. Taken from (Stuckey et al., 2013). 
 
 
As show in the Table 1, a variety of viral vectors have been exploited to introduce TRAIL 
into mesenchymal stem cells for their use in cell based therapies in animal tumor models. 
But the safety of these viral systems is still problematic and under controversial debate. In 
particular there are two major concerns. The first one is the immune response reaction, 
due to the fact that some viral vectors are immunogenic and show instability of transgene 
expression, that can cause severe reactions in the patient. The second concern is about 
the site of integration of the DNA into the genome of the cells, which should not destroy 
genes essential for the physiologic behavior of the MSCs, otherwise they might 
themselves generate cancer. Although non-viral methods have lower efficiency compared 
to viral-based methods, they are safe, non-infectious, and non-immunogenic, have 
negligible toxicity, can be produced simply on a large scale and have the capacity to carry 
larger therapeutic genes (Schaffert et al., 2008). Nevertheless, only a small number of 
studies have used non-viral methods to transfect stem cells with TRAIL (Choi et al., 2011 
and Hu et al., 2012). This emphasizes the importance to explore the possibility to use 
MSCs as delivery vehicle based on non-viral transfection for tumor treatments. 
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1.5 Goals 
 
Despite extensive research aimed to develop new therapeutic strategies against cancer, it 
still remains one of the first causes of death. Recent evidence reported the existence of a 
sub-population of quiescent cells within the tumor mass named cancer stem cells. These 
cells are typically in a quiescent status which makes them resistant to standard anti-
cancer therapies such as chemotherapy and radiotherapy. In addition, due to their self-
renewal and differentiation abilities, CSCs are considered responsible for tumor initiation 
and relapse even after apparent complete response to systemic therapy. In this context, 
targeting the CSC population will be critical to advance the efficacy of cancer treatment. 
Based on this new finding, in the first part of my thesis, I exploited the strategy of targeting 
delivery to CSCs of anticancer proteins generating and testing TRAIL fusion proteins 
directed against two of the most promising CSC markers, CD133 and LGR5.     
In the second part, I investigated the feasibility and the safety of a novel cell based 
therapeutic approach for cancer treatment. This method exploits unique features exert by 
mesenchymal stem cells, such as tumor homing ability and immunosuppressive 
properties. Due to these capabilities, several studies tested the mesenchymal stem cell as 
a delivery system for local expression of therapeutic reagents. Additionally, with this 
approach the major limitations observed during standard protein therapy, including short 
half-life and fast renal clearance, can be overcome. Based on these concepts, the second 
part of my thesis addressed  the potential use of MSCs as carrier system for a stable and 
long in situ production of the therapeutic TRAIL protein. In particular the specific aim was 
to exploit non-viral transfection methods for generation of a stable producer MSC line and 
investigate their functional activity in various in vitro as well as in an in vivo  tumor model.  
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2 Materials and Methods 
 
2.1 Materials 
  
2.1.1 Equipment  
 
Table 2: List of instruments used in this thesis 
Equipment  Company  
Balances: 440-39N, 440-333N and ALJ 120-4  Kern, Germany  
Beckman Coulter Avanti J-30I Centrifuge (Rotor J20)  
(for amounts up to 250 ml)  
Beckman Coulter, Krefeld  
Beckman J2-MC Centrifuge (Rotor JA14)  
(for amounts up to 250 ml)  
Beckman Coulter, Krefeld  
CK2 (standard light microscope)  Olympus, Hamburg  
Concentrator (Vivaspin) GE Healthcare, Germany 
Cytomics FC 500 (FACS)  Beckman Coulter, Krefeld  
Eppendorf Centrifuge 5415D (Rotor F45-24-11)  
(for amounts up to 1.5 ml)  
Eppendorf, Hamburg  
Eppendorf Centrifuge 5415R (Rotor F45-24-11)  
(for amounts up to 1.5 ml)  
Eppendorf, Hamburg  
EVOS fl inverted fluorescence microscope AMG, Mill Creek, USA 
Film Processor Curix 60  Agfa, Düsseldorf  
HBT-1-131 (Heat block) BioTech, Bovenden  
Incubator for bacteria BD53 Binder, Stuttgart 
Incubator for cell culture (CO2 Inkubator 2424-2) Zapf, Sarstedt 
Jouan CR422 Centrifuge (low speed for cell culture)  Jouan Quality system  
Mini-PROTEAN 3 Electrophoresis Cell System  BioRad, Munich 
MKR 13 (orbital microplate shaker)  HLC BioTech, Bovenden  
NanoDrop® ND-1000 (Spectrophotometer)  peQLab, Erlangen  
Neubauer counting chamber 0.0025 mm
2
 Marienfeld, Lauda-Königshofen  
Nuaire IR Autoflow, CO2 Water-Jacketed Incubator  Zapf Instruments  
pH meter FiveEasy  Mettler Toledo, Giessen 
Pipettes (1 – 10 µl / 2 - 20 μl / 20 - 200 μl / 100 - 
1000 μl)  
Gilson / Eppendorf  
Robo Cycler Gradient 96 (PCR cycler)  Stratagene  
Sterile bench W90 Waldner-Laboreinrichtungen, Germany 
Tecan Infinite M200 (ELISA plate Reader) Tecan, Grödig, Austria 
TransBlot SD, Semidry transfer cell BioRad, Munich 
Transilluminator Bio View UV light  Biostep, Jahnsdorf   
Vortex   Sky Line Elmi Ltd., Latvia 
Water Purification Milli-Q Reference  Millipore, Schwalbach 
Waterbath MA6, Lauda, Lauda-Königshofen 
HPLC-System Waters Alliance 2695  Waters Cooperation, Milford, USA  
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2.1.2 Consumables  
 
 
Table 3: List of consumables used in this thesis 
Consumable  Company  
0.2 μm filter for sterile filtration  Sarstedt, Nümbrecht  
6-well glass bottom cell culture dishes  MatTek Corporation  
96-well E-plates  Roche Diagnostics, Mannheim  
blotting paper, 3 mm Whatman  Schleicher Schuell, Dassel  
cell culture dishes  Greiner, Frickenhausen  
cell culture flasks  Greiner, Frickenhausen  
cell culture plates  Greiner, Frickenhausen  
Cryo vials 1ml  Greiner, Frickenhausen  
D-Tube™ Dialyzer Mini (MW cut-off 6 - 8 kDa)  Calbiochem, Merck, Darmstadt  
falcon tubes (15 ml and 50 ml)  Greiner, Frickenhausen  
HPLC columns: BioSep-SEC-S2000, -S3000 or 
Yarra SEC-3000  
Phenomenex, Aschaffenburg  
Nitrocellulose Transfer Membrane  Pall Life Sciences, East Hills, USA  
pipette tips (1 - 20 μl; 20 - 200 μl; 200 - 1000 μl)  Greiner, Frickenhausen  
pipettes (5 ml, 10 ml and 25 ml)  Greiner, Frickenhausen  
Poly-Prep® columns  Bio-Rad, Munich  
Protino® Ni-NTA agarose beads  Machery-Nagel, Düren  
PVDF blotting membrane  Carl Roth GmbH & Co, Karlsruhe  
reaction tubes 1.5 ml (standard and safe-lock)  Eppendorf, Hamburg  
replica dishes  Sterilin Limited, Newport, UK  
Transwells (24-well plate plus inserts) for cell 
migration assays, (0.8 μm pore size)  
Costar/Vitaris AG, Baar, Germany  
X-ray films  CEA, Strangnas, Sweden  
  
2.1.3 Chemical and solvent  
 
Table 4: List of chemicals and solvents and used in this thesis 
Chemical and solvent  Company  
3, 3’, 5, 5’-Tetramethylbenzidine (TMB) BD Bioscience, Heidelberg 
Agarose  Carl Roth GmbH & Co, Karlsruhe  
Alexa Fluor 568® -labeled phalloidin  Molecular Probes /Invitrogen, Carlsbad, USA  
Ammonium persulfate (APS)  Carl Roth GmbH & Co, Karlsruhe  
Ampicillin  Roth, Karlsruhe  
Anti-Flag M2 Affinity Gel  Sigma-Aldrich, München  
Ascorbic acid-2-phosphate Sigma-Aldrich, München 
Bromphenol blue  Serva, Heidelberg  
Calcium chloride (CaCl2)  Merck, Darmstadt  
Coomassie Brilliant Blue  SERVA Electrophoresis, Heidelberg  
Crystal violet  Merck, Darmstadt  
Dexamethasone Lonza, Köln 
Dimethylsulfoxide (DMSO)  Carl Roth GmbH & Co, Karlsruhe  
Disodium hydrogen phosphate (Na2HPO4)  Carl Roth GmbH & Co, Karlsruhe  
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Chemical and solvent  Company  
Dithiothreitol (DTT)  Carl Roth GmbH & Co, Karlsruhe  
EGF R&D System 
Ethanol (EtOH)  Carl Roth GmbH & Co, Karlsruhe  
Ethidium bromide (EtBr)  Roche Diagnostics, Mannheim  
Fluoromount-G Southern Biotech, Birmingham, USA 
GeneRuler 1 kb (DNA ladder)  Thermo Fisher Scientific, Waltham, USA 
Glycerol  Carl Roth GmbH & Co, Karlsruhe  
Glycine  Carl Roth GmbH & Co, Karlsruhe  
H2SO4 Carl Roth GmbH & Co, Karlsruhe 
Human insulin Sigma-Aldrich, Deisenhofen 
Hydrochloric acid (HCl)  Carl Roth GmbH & Co, Karlsruhe  
IBMX (3-Isobutyl-1-methylxanthine) Sigma-Aldrich, Deisenhofen 
Imidazole Carl Roth GmbH & Co, Karlsruhe 
Indomethacin Sigma-Aldrich, Deisenhofen 
Isopropanol  Carl Roth GmbH & Co, Karlsruhe  
KH2PO4 Carl Roth GmbH & Co., Karlsruhe 
Methanol (MeOH)  Carl Roth GmbH & Co, Karlsruhe  
N,N,N,N-Tetramethylethyldiamine (TEMED)  Carl Roth GmbH & Co, Karlsruhe  
Na2HPO4 Carl Roth GmbH & Co., Karlsruhe 
PageRuler prestained protein ladder  Thermo Scientific, Rockford, USA 
Paraformaldehyde (PFA)  Carl Roth GmbH & Co, Karlsruhe  
Peptone Carl Roth GmbH & Co., Karlsruhe 
Phenylmethylsulphonyl fluoride (PMSF)  Sigma-Aldrich, München  
Potassium acetate  Sigma-Aldrich, München  
Potassium chloride (KCl)  Carl Roth GmbH & Co, Karlsruhe  
Propidium iodide (PI)  Invitrogen, Karlsruhe  
Protein G Sepharose beads  KPL, Gaithersburg, USA  
Sodium azide Sigma-Aldrich, Taufkirchen 
Sodium chloride (NaCl)  Carl Roth GmbH & Co, Karlsruhe  
Sodium dodecyl sulfate (SDS)  Carl Roth GmbH & Co, Karlsruhe  
Sodium hydroxide (NaOH) Carl Roth GmbH & Co., Karlsruhe 
Tris-hydroxymethyl-aminomethane (Tris)  Carl Roth GmbH & Co, Karlsruhe  
Triton X-100  Carl Roth GmbH & Co, Karlsruhe  
Tween 20  Carl Roth GmbH & Co, Karlsruhe  
β-Glycerophosphate  Sigma-Aldrich, München  
β-Mercaptoethanol  Carl Roth GmbH & Co, Karlsruhe  
  
 
2.1.4 Buffers and solutions  
 
 
Table 5: List of buffers and solutions used in this thesis 
Buffer and Solution  Composition  
1% Alizarin red solution 100 mg alizarin red solved in 10 ml H2O, pH adjusted to 
pH 6.4 
10% APS solution  10% (w/v) APS in H2O  
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Buffer and Solution  Composition  
AP buffer  100 mM Tris pH 9.5, 100 mM NaCl, 5 mM MgCl2  
Blocking solution (microscopy)  5% (v/v) bovine serum, 0.1% (v/v) Tween 20 in PBS  
Blocking solution (Western blot)  5% (w/v) milk powder, 0.1 % (v/v) Tween 20 in PBS  
Blotting buffer  200 mM glycine, 25 mM Tris base, 20% (v/v),methanol  
Cell freezing solution  10% (v/v) DMSO in FCS  
Competent cell solution A 0.1 M CaCl2 in 1x PBS 
Competent cell solution B 20% (v/v) glycerol, 50 mM CaCl2 in 1x PBS 
Coomassie blue solution  0.008% (w/w) Coomassie Brilliant Blue G-250, 35 mM HCl 
in H2O  
Crystal violet staining solution  20% (v/v) methanol, 0.5% (m/v) crystal violet in H2O  
DNA loading buffer (5x)  25% (v/v) glycerol, 0.02% (w/v) bromphenol blue in 5x 
TAE buffer  
ELISA – blocking solution  2% (m/v) dry milk powder in 1x PBS  
ELISA – developing solution  0.1 mg/ml TMP, 100 mM sodium acetate buffer pH 6.0, 
0.006% (v/v) H2O2  
ELISA – stopping solution  1 M H2SO4  
ELISA – washing solution  0.05% (v/v) Tween20 in 1x PBS  
Hemalaun solution 1 g hämatoxylin, 0.2 g NaIO3, 50 g aluminium potassium 
sulphate, 50 g chloral hydrate, 1 g citric acid, H2O added 
to 1 
IMAC elution buffer  250 mM imidazole in 1x sodium phosphate buffer  
 
IMAC wash buffer  35 mM imidazole in 1x sodium phosphate buffer  
Laemmli SDS sample buffer (5x)  400 mM Tris, pH 6.8, 500 mM dithiothreitol, 50% (v/v) 
glycerol, 10% (w/v) SDS, 0.2% (w/v), bromophenol blue  
Oil red-o solution 6 parts of 0.5% oil red O solution solved in isopropanol 
with 4 parts dH2O 
PBA 2% (v/v) FBS, 0.02% (w/v) NaN3 in 1x PBS  
PBS-Tween  0.05% (v/v) Tween20 in PBS  
Periplasmic preparation buffer (PPB)  30 mM Tris-HCl pH 8.0, 1 mM EDTA, 20% (w/v) sucrose 
in H2O  
 
PFA  4% (w/v) in PBS  
Phosphate Buffered Saline (PBS)  140 mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 1.5 mM 
KH2PO4  
SDS-PAGE running buffer  25 mM Tris pH 8.8, 192 mM glycine, 0.1% SDS,  
Separating gel solution  10%, 12,5% or 15% (v/v) acrylamide, 375 mM Tris, pH 
8.8, 0.1% (v/v) SDS, 0.1% APS, 0.1% TEMED in H2O  
Stacking gel solution 5% (v/v) acrylamide, 130 mM Tris, pH 6.8, 0.1% (v/v) 
SDS, 0.1% APS, 0.1% TEMED in H2O  
TAE (Tris-Acetat-EDTA) 40 mM Tris-acetate, 1 mM EDTA, 
TE buffer (10x)  M Tris-HCl, 10 mM EDTA, pH 7.5  
Tris-Acetat-EDTA (TAE), pH 8,0  40 mM Tris-acetate, 1 mM EDTA, pH 8.3  
Washing solution (Western blot) 0.05% (v/v) Tween 20 in 1x PBS  
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2.1.5 Kits 
 
Table 6: List of kits used in this thesis 
 
 
2.1.6 Enzymes 
 
Table 7: List of enzymes used in this thesis 
 
 
2.1.7 Cell lines, media and reagents 
 
Table 8: List of cell lines and media used in this thesis 
  
 
Table 9: List of cell culture reagents, media and antibiotics used in this thesis 
Kit Company 
BD OptEIA™ human TRAIL ELISA Set BD Biosciences, Heidelberg 
MaxDiscovery™ ALT Enzymatic Assay kit BIOO Scientific, Austin, USA 
NucleoBond® Xtra Midi  Macherey-Nagel, Düren  
NucleoSpin® Plasmid  Macherey-Nagel, Düren  
NucleoSpin®Gel and PCR Clean-up Macherey-Nagel, Düren  
Enzyme Company 
DreamTaq™ Green PCR Master Mix Fermentas, St. Leon-Rot 
FastAP™ Thermosensitive Alkaline Phosphatase Fermentas, St. Leon-Rot 
Lysozyme  Roche Diagnostics, Mannheim  
Restriction enzymes: BshTI (AgeI), NotI, SfiI Fermentas, St. Leon-Rot 
T4 DNA ligase Fermentas, St. Leon-Rot 
Cell line Medium Origin 
Caco2 RPMI 1640 + 10% (v/v) FCS Human colon adenocarcinoma 
Colo 205 RPMI 1640 + 10% (v/v) FCS Human colon adenocarcinoma  
HCT116 RPMI 1640 + 10% (v/v) FCS Human colon carcinoma  
HEK293T RPMI 1640 + 5% (v/v) FCS  Human embryonic kidney  
LoVo RPMI 1640 + 10% (v/v) FCS Human colon adenocarcinoma 
M2 α-MEM + 10% (v/v) FBS Mouse bone marrow 
Product Company 
10x Trypsin EDTA Life Technologies, Darmstadt 
Alpha-MEM Eagle Genaxxon bioscience, Ulm 
Anti TRAIL antibody Enzo Life Sciences, Lörrach 
Bortezomib  Velcade®, kindly provided by Dr. Thomas Mürdter (Institute of 
Clinical Pharmacology, Dr. Margarete Fischer-Bosch 
Foundation, Stuttgart) 
FBS (fetal bovine serum) GE Healthcare Bioscience, Austria 
FCS (fetal calf serum) Thermo Fisher Scientific, Waltham, USA 
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2.1.8 Antibodies 
 
Table 10: List of antibodies used in this thesis 
Antibody Species Dilution Company 
Alexa Fluor-568 
Phalloidin 
goat mAb 1:500 (IF) Invitrogen, San Diego, USA 
Anti-CD105-PE mouse mAb 1:100 (FC) BioLegend, London UK 
Anti-CD133-PE mouse mAb 1:50 (FC) Miltenyi Biotec, Köln 
Anti-CD44-PE mouse mAb 1:100 (FC) BioLegend, London UK 
Anti-CD71-PE mouse mAb 1:100 (FC) BioLegend, London UK 
Anti-CD9-PE mouse mAb 1:100 (FC) BioLegend, London UK 
Anti-cleaved caspase 3 
(Asp 175) 
rabbit mAb  1:1500 (FC) Cell Signaling, Frankfurt (Main) 
Anti-FLAG (DYDDDDK) mouse mAb 1:200 (WB) Sigma-Aldrich, St. Louis, USA 
Anti-Isotype IgG2a-PE rat mAb 1:100 (FC) BioLegend, London UK 
Anti-LGR5-PE mouse mAb 1:50 (FC) Miltenyi Biotec, Köln 
Anti-rabbit-FITC goat mAb 1:100 (FC) Sigma-Aldrich, St. Louis, USA 
Anti-TRAIL mouse mAb 1:80 (WB) R&D Systems, Wiesbaden 
 
  
2.1.9 Bacteria culture: strain, media and reagents 
 
Table 11: List of bacterial strain used in this thesis 
 
Table 12: List of bacteria media and reagents used in this thesis 
Medium and reagent Composition Company 
Ampicillin 100 mg/ml in H2O  Roth, Karlsruhe 
IPTG  Isopropyl-β-D-thiogalactopyranoside, 1 
M in H2O  
Gebru Biochemicals, 
Gaiberg  
Product Company 
G418 Enzo Life Sciences, Lörrach 
Heparin B-Brawn, Melsungen 
Penicillin/streptomycin (100x)  Invitrogen, San Diego 
Polyethyleneimine (PEI) Polysciences Europe GmbH, Eppelheim 
RPMI 1640 and OptiMEM Invitrogen, San Diego  
Zeocin™  Invitrogen, San Diego, USA  
Bacterial strain Description 
E. coli TG1 Genotype: supE thi-1 Δ(lac-proAB) Δ(mcrB-hsdSM)5 (rK– 
mK–) [F´ traD36 proAB lacIqZΔM15] (Stratagene, La Jolla, 
USA) 
E. coli DH5α Genotype: F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR 
nupG 80dlacZM15 (lacZYAargF) U169, hsdR17(rK - mK +), 
λ– (Stratagene, La Jolla, USA) 
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Medium and reagent Composition Company 
LB Amp,Glc agar plates  LB-medium, 2 % (w/v) agar, after 
autoclaving added ampicillin (f.c.: 
100 μg/ml) and 1 % (w/v) glucose  
 
LB-medium  1 % (w/v) peptone, 0.5 % (w/v) yeast 
extract, 0.5 % (w/v) NaCl in H2O 
 
TY-medium 1.6 % (w/v) pepton, 1 % (w/v) yeast 
extract, 0.5 % (w/v) NaCl in H2O  
 
  
 
2.1.10 Vectors and plasmid 
 
Table 13: List of vectors used in this thesis 
 
 
Table 14: List of plasmids used in this thesis 
 
2.1.11 Primers 
All primers were synthesized by Biomers (Ulm), dissolved in dH2O (f.c.: 50 μM) and stored 
at -20 °C. 
 
Table 15: List of primers used in this thesis 
Vector Description and source 
pAB1 Vector for prokaryotic expression in periplasm of E.coli TG1 
(Kontermann et al., 1997) 
pCR3 Eukaryotic expression vector (Invitrogen, Karlsruhe) 
pAB1-4D5 Murine vector for prokaryotic expression in periplasm of 
E.coli TG1  
Plasmid Description 
 pCR3-DbEGFR-scTRAIL Kindly provided by Dr. M. Siegemund (Siegemund 
et al., 2012) 
pCR3-DbEGFR-Glyco-scTRAIL Kindly provided by Dr. M. Siegemund (Siegemund 
et al., 2012) 
humanized  pAB1- scFvαCD133  Cloned in this work 
humanized  pAB1- scFv αLGR5 Cloned  in this work 
DbαCD133-scTRAIL Cloned  in this work 
DbαLGR5-scTRAIL Cloned  in this work 
murine  pAB14D5-scFvαCD133 Cloned  in this work 
murine  pAB14D5-scFv αLGR5 Cloned  in this work 
Nr. Primers for cloning Sequence 5’-3’ 
1 SfiI-scFvαCD133-For GCACGATCTCAGATCCTCCGCCGCCACTCG 
2 SfiI-scFvαCD133-Rev CCACGTACCGGTCAGGTGCAGCTGGTGCAGTC 
3 NotI-scFvαCD133-For GGGCCCAAGCTTGGTACCCGTTCATTGC 
4 NotI-scFvαCD133-Rev GCGGAGGATCTGAGATCGTGCTGACACAGAGC 
5 SfiI-scFvαLGR5-For CAGAAGAAAGTGAACCGCCTCCACTCGAGACG 
6 SfiI-scFvα LGR5-Rev CACGATCTCAGATCCTCCGCCACTCGTTCAC 
7 NotI-scFvα LGR5-For CCCTCGTGACAGTCTCGAGTGGCGGAGGATC 
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2.1.12 Programs and online tools 
 
Table 16: List of programs and online tools used in this thesis 
 
 
2.2    Methods 
 
2.2.1 Cloning 
 
2.2.1.1 Cloning of DbαCD133-scTRAIL and DbαLGR5-scTRAIL 
 
The DNA sequences of murine scFv-CD133 and scFv-LGR5 were synthetically produced 
(Geneart, Regensburg, Germany) according to the patent WO2011149493 (Valera) for 
CD133 and to the patent WO201016766 (Clevers) for LGR5. Then, both scFv fragments 
were digested by AgeI/NotI and cloned into the murine vector pAB1-4D5, digested with 
the same enzymes, resulting in pAB1-4D5-scFvαCD133 and pAB1-4D5-scFvαLGR5. Then, 
pAB1-4D5-scFvαCD133 and pAB1-4D5-scFvαLGR5 were amplified by PCR using the primers 
(for scFvαCD133 Nr. 1, 2, 3, 4; for scFvαLGR5 Nr. 5, 6, 7, 8), digested by SfiI/NotI and then 
ligated into the vector pAB1, also digested with SfiI/NotI, resulting in humanized pAb1-
scFvαCD133 (hu-scFvαCD133) and pAb1-scFvαLGR5 (hu-scFvαLGR5). For the generation of 
scTRAIL fusion proteins, hu-scFvαCD133 and hu-scFvαLGR5 were amplified by PCR using the 
Nr. Primers for cloning Sequence 5’-3’ 
8 NotI-scFvα LGR5-Rev CACGATCTCAGATCCTCCGCCACTCGAGAC 
9 AgeI-DbαCD133-scTRAIL-For  ATATATACCGGTCAGGTGCAGCTGGTGCAGTC 
10 AgeI-DbαCD133-scTRAIL-Rev GCTGGATATCAGATCCTCCGCCTCCGCTAG 
11 NotI-DbαCD133-scTRAIL-For  GCGGAGGATCTGATATCCAGCTGACCCAGAGC 
12 NotI-DbαCD133-scTRAIL-Rev ATATATGCGGCCGCTCTCTTGATTTCC 
13 AgeI-DbαLGR5-scTRAIL-For  ATATATACCGGTGAAGTGCAGCTGGTGGAATCTG 
14 AgeI-Dbα LGR5-scTRAIL-Rev CTGGATATCTGATCCTCCGCCTCCGCTAG 
15 NotI-Dbα LGR5-scTRAIL-For  GCGGAGGATCAGATATCCAGATGACCCAGAGCC 
16 NotI-Dbα LGR5-scTRAIL-Rev ATATATGCGGCCGCTCTCTTGATTTCC 
Programs and online tools Reference 
Clone Manager Professional 7  Scientific & Educational software, Carey, USA  
ExPASy Prot Param Tool  http://web.expasy.org/protparam/  
FlowJo http://www.flowjo.com 
GraphPad Prism 5.01  GraphPad software, La Jolla, USA  
ImageJ  http://rsb.info.nih.gov/ij/  
Microsoft® Word and Excel  Microsoft Corporation  
RCSB protein databank  http://www.pdb.org/pdb/home/home.do  
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respective template pAb1-scFvαCD133 and pAb1-scFvαLGR5 and primers (for CD133 Nr. 9, 
10, 11, 12; for LGR5 Nr. 13, 14, 15, 16). Subsequently, the PCR products were digested 
by AgeI/NotI and cloned into the vector pCR3-Dbglyco-scTRAIL, resulting in DbαCD133-
scTRAIL and Db αLGR5-scTRAIL. Used primers are listed in Table 15. 
 
2.2.1.2 Polymerase chain reaction  
 
Polymerase chain reaction (PCR) was used with the aim of amplifying desired sequences, 
from vector template, with the necessary restriction sites. Usually a PCR reaction 
contained: 
- 5 μl pfu-polymerase buffer (10 x) + MgSO4  
- 1μl Template (50 ng/μl) 
- 1 μl Forward primer (10 pmol/μl)  
- 1 μl Reverse primer (10 pmol/μl) 
- 2 μl dNTPs (5 mM)  
- 1 μl pfu-DNA-polymerase (2.5 U/μl)  
- dH2O for a final volume of 40μl 
 
The amplification of DNA was performed using the PCR program described in Table 17. 
The elongation time was dependent on the resulting PCR product. For the pfu polymerase 
was assumed a synthesis rate of 1000 nucleotides per minute, with a minimal elongation 
time of 0.5 min. Next, the PCR product was loaded on an agarose gel and separated from 
primers and template DNA. 
 
Table 17: PCR program 
PCR step  Temperature (°C)  Time (minutes) Number of cycles 
Initial denaturation  94 5 1x 
Denaturation  94 0.5 33x 
Annealing  50 0.5 33x 
Elongation  72 dependent 33x 
Final elongation  72 5 1x 
 
2.2.1.3 Restriction digestion 
 
In a final volume of 50 μl, the vector DNA (5 μg) or the entire DNA purified from agarose 
gel was digested. For double digests, both enzymes were added to the mixture when 
temperatures and buffer conditions were the same and incubated for 2 h. Otherwise 
digestions were performed consecutively with additional purification step. Then, the buffer 
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exchange was performed with the NucleoSpin Gel and PCR Clean-up kit. Using Fast 
alkaline phosphatase (1 μl), for 1h at 37°C, the vector DNA was dephosphorylated, after 
the last digestion step. Finally the fragments obtained were separated and analyzed by 
agarose gel electrophoresis. 
 
2.2.1.4 DNA electrophoresis and gel extraction 
 
The DNA fragments obtained by digestion or after amplification were analyzed and 
purified by horizontal agarose gel electrophoresis. Gels were prepared by dissolving 1 – 2 
% (w/v) of agarose, according to the size of the fragments, in TAE boiling buffer. Next, a 
final concentration of 1 μg/ml of ethidium bromide was added. DNA was mixed with DNA 
loading buffer and loaded to the agarose gel (80 V, 30 min). DNA fragments were 
visualized under ultra violet light and relevant bands were excised and purified according 
to manufacturer’s protocol with a NucleoSpin Gel and PCR Clean-up kit. 
 
2.2.1.5 Preparation of chemically competent E. coli cells  
 
After overnight culture, E. coli TG1 or DH5α were inoculated in 1 l of LB medium (dilution 
1:100) and grown, at 37 °C under shaking conditions (170 rpm), until they reached an 
OD600 of 0.5 to 0.6. Next, cells were chilled on ice for 15 minutes, harvested by 
centrifugation (4000 g, 10 min, 4 °C) and the pellet was resuspended on ice with 50 ml of 
competent cell solution A (0.1 M CaCl2 in 1x PBS), followed by incubation for 30 minutes 
on ice. An additional centrifugation step was performed (4000 g, 5 min, 4 °C) and the 
bacteria pellet was resuspended on ice with 10 ml competent cell solution B (20 % (v/v) 
glycerol/50mM CaCl2 in 1x PBS). The resulting competent cells were immediately frozen 
in liquid nitrogen and stored at -80 °C. 
 
2.2.1.6 Ligation of DNA fragments and transformation of bacteria 
 
Ligation of DNA fragments and linerarized vector fragments were performed using T4 
DNA-ligase with a total DNA amount of 250 ng and a molar ratio of vector to insert of 1:3. 
For the ligation reaction, 1 U of T4 DNA ligase was incubated with the DNA fragments for 
1 h at 25°C, in a final volume of 20 μl. The latter was added to 100 μl of competent E. coli, 
previously thawed on ice, and incubated for 45 min on ice. Next, bacteria were subjected 
to heat shock at 42 °C for 45 sec and were subsequently placed on ice for 1 min, followed 
by resuspension in 1 ml of LB medium. After recovery, cells were incubated for 45 min at 
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37°C. Finally, bacteria were harvested by centrifugation (3000 g, 2 min) and were plated 
on LB agar plates containing the selective antibiotic and incubated overnight at 37 °C. 
 
2.2.1.7 Plasmid DNA isolation and sequence analysis 
 
One single clone, from the LBAmp,Glu plate or from PCR screening, was inoculated into 5 ml 
LB medium for Mini preparation or 100 ml for Midi, containing the respective antibiotic. 
After overnight incubation at 37 °C, bacteria were harvested by centrifugation and DNA 
was purified according to manufacturer’s protocol with the NucleoSpin Plasmid kit and the 
NuceloBond Xtra Midi kit for Mini and Midi preparation respectively. Sequence 
confirmation of the final expression vector was performed by GATC Biotech AG 
(Konstanz, Germany) using the corresponding primers from Table 15. 
 
2.2.2 Cell culture 
 
Mouse bone marrow derived MSCs (M2) were kindly provided by Dr. Angelika Hausser 
(IZI, University of Stuttgart, Germany). These cells were cultivated under sterile 
conditions, at 37 °C in a 5% CO2 humidified atmosphere, in alpha-MEM supplemented 
with 10% FBS plus 1% Penicillin/Streptomycin (Pen/Step). MSCs were passaged, using 
trypsin-EDTA for cell detachment, at a confluence of 70% every 3-4 days if not mentioned 
otherwise. 
Caco2, Colo205, HCT116, HEK293 and LoVo cells were obtained from the ATCC 
(Manassas, VA, USA) and cultured, at 37 °C and 5% CO2, in RPMI-1640 medium 
(Invitrogen) supplemented with 10% FCS (Thermo Fisher Scientific), excepting HEK293 
where 5% FCS was added to the medium. Before reaching confluence, cells were 
passaged and maintained in culture for not longer than three month. New cultures of each 
cell line were established from frozen stocks containing the respective serum 
supplemented with 10% DMSO which were stored in liquid nitrogen. All cell lines grew in 
adherent condition. 
 
2.2.3 Cell transfection 
 
All cell lines were transfected with polyethyleneimine (PEI) using a ratio 1:3 for DNA and 
PEI. The day before, 1 million cells were seeded in a 6-well plate in a final volume of 2 ml 
and allowed to adhere overnight. The next day, cell culture medium was removed and 1.5 
ml of serum free Opti-MEM was added. Then, 300 μl of Opti-MEM were incubated with 12 
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μg of PEI for 5 min a RT. Next, 4 μg of plasmid DNA was added to the mixture and 
vortexed. After 20 min incubation, the mix was carefully added drop-wise to the cells. After 
overnight incubation at 37 °C Opti-MEM was removed and cells were transferred into a 
flask and allowed to grow in cell culture medium for 24 h. Next, in order to select the 
transfected cells, G418 (f.c.: 150 μg/ml and 250 μg/ml for MSCs or 200 μg/ml for HEK293) 
was added to the medium. After establishment of stably transfected cell pools (2-3 
weeks), cells were used for further studies.  
 
2.2.4 Single clone selection 
 
In order to obtain single clone cell lines, 18 h after PEI transfection, MSCs or HEK393 
cells were immediately seeded in 96-well plates, performing limiting dilutions with a 
statistical density of 1 cell/well, in the presence of antibiotic (G418) as selection pressure. 
After establishment of colonies, the medium was changed every 2 or 3 days after a 
washing step with sterile PBS. During the selection process, untransfected cells died and 
positively transfected cells survived and replicated. The 96-well plates were analyzed 
every 3 or 4 days and the growing clones were monitored for their confluence. When cell 
confluence was around 70% in the wells with growing cells (41 days after seeding for 
MSCs and around 14 days for HEK293) a dot blot was performed. The latter, in order to 
select clones expressing the recombinant proteins, was done using culture medium from 
each well after 3 days of cultivation. According to the dot blot results, positive clones were 
transferred into flasks and expanded in vitro. The productivity was tested by ELISA, 
analyzing cell medium from each clone after 3 days of cultivation, seeding the same 
number of cells. Based on this procedure, the generated cell lines were assumed to be a 
single cell derived cell lines. 
 
2.2.5 Expression and purification of recombinant proteins 
 
2.2.5.1 Periplasmic protein expression in E. coli TG1 
 
The scFv fragments were produced and purified from the periplasm of E. coli TG1. In 
particular, a pre-culture of transformed bacteria was grown overnight, at 37 °C and 
shaking condition (170 rpm), in 20 ml of TY medium with 1 % (w/v) glucose and 100 μg 
ampicillin/ml. Next, 2 l of TY medium, containing ampicillin and 0.1 % (w/v) glucose, were 
inoculated with a dilution 1:100 of the overnight culture and cells were grown (37 °C, 
shaking 170 rpm) until the OD600 reached 0.8-1.0. At this time point, IPTG (1 mM) was 
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added to the cell suspension, in order to induce the protein expression and incubation was 
performed at 25 °C for 4 h on a shaker (170 rpm). Then, cells were harvested (10 min, 4 
°C, 6.000 g) and the cell pellet was resuspended with 100 ml of cold periplasmic 
preparation buffer (PPB). All the following steps were performed on ice and with chilled 
liquids and centrifuges. The cell wall was lysed by incubation with lysozyme (50 μg/ml) for 
30 min on ice, followed by addition of MgSO4 (10 mM) in order to stabilize the 
spheroblasts. Then, the periplasmic preparation (supernatant) was collected after 
centrifugation (10 min, 10.000 g) and dialyzed overnight against 5 l of PBS. After 
centrifugation (10 min, 10.000 g), in order to remove pellet aggregations, the dialyzed 
periplasmic preparation was used for purification via Ni-NTA-IMAC (as described in 
2.2.5.3). 
 
2.2.5.2 Protein expression in mammalian cells 
 
After the selection of stably transfected cell lines, cells were grow in RPMI medium with 
5% FCS, until confluence was around 80 %. At this time point, culture medium was 
exchanged with serum free Opti-MEM, supplemented with ZnCl2 (50 μM). The latter was 
collected every 2-3 days, after centrifugation (20 min, 2000 g, 4 °C) in order to remove 
cells from the suspension, and stored at 4 °C. Then, proteins were purified using FLAG 
affinity chromatography (2.2.5.4) for proteins with FLAG-tag or by Immobilized Metal 
Affinity Chromatography (2.2.5.3) for 6xHis-tagged proteins. 
 
2.2.5.3 Immobilized metal affinity chromatography (IMAC)  
 
IMAC was used as  a batch purification method for all recombinant proteins comprising a 
6xHis-tag. After equilibration of the Ni-NTA-agarose beads with 8 ml of PBS, the dialyzed 
periplasmic preparation (2.2.5.1) was incubated with the beads at 4 °C for 2-3 h on a roller 
mixer. Next, the beads were loaded in an empty column and unspecific bound proteins 
were removed with 40 column volumes of IMAC wash buffer, containing 25 mM imidazole. 
Qualitative Bradford assay was performed (90 μl Bradford solution + 10 μl fraction) to test 
the protein content of wash and elution fractions, and blue color indicated presence of 
proteins. The specifically bound proteins were eluted from the beads by IMAC elution 
buffer containing 250 nM imidazole. Each elution fraction (250 μl) was analyzed by 
Bradford and those fractions containing the highest amount of proteins were pooled and 
dialyzed overnight against 5 l PBS at 4 °C, followed by SDS-PAGE and Western blot 
analysis. 
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2.2.5.4 Purification by FLAG affinity chromatography 
 
The anti-FLAG antibody agarose was used for purification of recombinant proteins 
comprising a FLAG-tag. After loading the anti-FLAG antibody agarose beads (2 ml) into a 
column, the material was washed first with 3 sequential column volume of low pH buffer 
(0.1 M glycine-HCl pH 3.5) and then 5 times with PBS in order to neutralize the pH and 
equilibrate. Next, the material was removed from the column and incubated in a glass 
bottle with the cell free culture supernatant (1 L), obtained as described in 2.2.5.2, at 4°C 
for 2 h on a roller mixer. After that, beads were harvested by centrifugation (2000 g, 10 
min, 4 °C) and transferred back into the empty column. Several washing steps with PBS 
were performed until unspecific bound proteins were completely washed away. This was 
verified by Bradford assay as described in 2.2.5.3. Specifically bound proteins were eluted 
by applying 10 ml FLAG-peptide (0.1 mg/ml) in PBS in aliquots of 1 column volume. After 
dialysis of eluates overnight against 5 l of PBS at 4 °C, proteins were concentrated using 
Vivaspin column concentrators (MW cut-off 30 kDa) and subsequently analyzed by SDS-
PAGE and Western blotting.  
 
2.2.6 Protein biochemical characterization 
 
2.2.6.1 Protein concentration  
 
The protein concentration was determined by using a spectrophotometer (NanoDrop). 
This latter calculates the amount of protein based on the absorbance of tryptophan and 
tyrosine residues at a wavelength of 280 nm. The molecular weight (MW [g/mol]) and the 
molar extinction coefficient ε [l/(mol x cm)] were determined by the online tool ‘ProtParam’ 
and the concentration was calculated with the following equation ( b [cm] represents the 
path length):     c [μg/ml] = OD280 x MW / (ε x b) 
  
2.2.6.2 SDS-PAGE and Coomassie staining  
 
Equal protein amounts (usually 3 μg for Coomassie staining or 1 μg for Western blotting) 
were mixed either in reducing or non-reducing 1x Laemmli SDS sample buffer, 
denaturated for 5 min at 95 °C and loaded, with standard protein for the determination of 
the molecular mass, on Tris/glycine SDS polyacrylamide gels. The gels consisted of 10%, 
12% or 15% polyacrylamide running gel and a stacking gel with 5% polyacrylamide. 
Electrophoresis was carried out by using a vertical gel electrophoresis chamber and the 
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gels were run in 1x SDS running buffer for approximately 1h at 50 mA. After washing the 
gel in water, it was stained with Coomassie solution for 1 hour on a shaker and finally 
destained in water.  
 
2.2.6.3 Western blotting  
 
For Western blot analysis, the proteins separated by SDS PAGE were transferred to 
polyvinylidene difluoride membrane (PVDF, Roth). The PVDF membrane was hydrated 
with 100% methanol and then equilibrated with blotting buffer. The proteins were blotted 
on membrane by semi-dry transfer using a semi-dry blotting chamber (Phase, Lübeck) 
and a constant current of approximately 150 mA (1.5 - 1.6 mA/cm2) for 1 hour and 30 min 
at room temperature. The voltage was limited to 15 V. The membrane was blocked with 
blocking solution (5 % dry milk in 1x PBS) at RT for at least 40 min and incubated 
overnight at 4 °C with the primary antibody (diluted according to the manufacturer’s 
instructions in blocking solution). The membrane was washed three times with 1x PBS-T 
and incubated with the appropriate secondary antibody (Horseradish Peroxidase (HRP) 
conjugate, 1:10000 dilution in blocking solution) for 1 hour at RT. After washing (3 times 
with 1x PBS-T) the membrane was treated with a peroxidase substrate (enhanced 
chemiluminescence (ECL) detection system from Pierce) according to the manufacturer’s 
instructions to visualize the signals and exposed to an X-ray film for different time points 
(5 sec up to 5 min). 
 
2.2.6.4 Size exclusion chromatography (SEC) 
 
In order to verify the purity and the integrity of purified proteins high performance liquid 
chromatography (HPLC) was performed using size exclusion columns. For each sample 
20 μl of protein with a concentration between 0.2 and 0.5 μg/μl was injected into the HPLC 
system and analyzed in a PBS mobile phase with a flow rate of 0.5 ml/min. The following 
standard proteins were used in order to determine the molecular mass of the purified 
proteins: thyroglobulin (669 kDa), β-amylase (200 kDa), bovine serum albumin (66 kDa), 
carbonic anhydrase (29 kDa) and FLAG peptide (1 kDa). 
 
2.2.7 Cell death assays 
 
Cells were seeded in 100 μl/well of culture medium in 96-well plates, Colo205 (40.000 
cells per well), MSCs (20.000 cells per well) HCT116 and LoVo (30.000 cells per well) and 
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allowed to grow overnight. The day after, cells were treated with serial dilutions of DbEGFR-
scTRAIL (starting from 3 nM; titration 1:3), DbCD133-scTRAIL and DbLGR5-scTRAIL (starting 
from 10 nM; titration 1:3) or with supernatant from transfected MSCs (dilutions 1:3, 1:9 
and 1:27), in triplicates. The neutralizing anti-TRAIL antibody (1 μg/ml) was used in 
combination with the fusion proteins or the supernatant from transfected MSCs  and the 
sensitizer bortezomib (7.5 ng/ml for HCT116 and 250 ng/ml for all other cell lines) was 
added 30 min before. After 18 hours of incubation at 37 °C, culture medium was removed 
and cell viability was analyzed. 50 μl of crystal violet staining solution (20 % (v/v) 
methanol, 0.5 % (m/v) crystal violet in dH2O) were added in each well and incubated at 
room temperature for 20 min. After abundant washing of the wells with H2O and air-drying 
(1-2 h), crystal violet was dissolved in 50 μl methanol and the absorbance was measured 
by an ELISA reader at 550 nm. 
 
2.2.8 Co-culture of MSCs and Colo205 
 
100.000 Colo205 cells/well were seeded in 24-well plates, in 600μl of MSC medium 
(alpha-MEM) and allowed to grow at 37°C. After overnight incubation, MSCs were added 
to the 24-well plate using different ratio of MSCs:Colo205 (1:5, 1:20, 1:50) in a final 
volume of 1 ml/well. Different treatments with bortezomib (250 or 7.5 ng/ml) and anti-
TRAIL antibody (1 μg/ml) were performed and analyzed by crystal violet staining as 
described in 2.2.7. 
 
2.2.9 Migration assay 
 
Into the bottom chamber of a transwell (0.8 μm pore size; Costar), 80.000 Colo205 cells 
were seeded in RPMI-1640 medium with 10% FCS. After overnight cultivation, medium 
was removed, transwells were washed three times with PBS, and alpha-MEM with 0.5% 
FBS was added. Into the upper chamber of the transwell, 15.000 cells for each MSC line, 
wild type (wt), clone #A1, clone #B12 or Mock, were seeded in medium containing 0,5% 
FBS and allowed to migrate for 8 hours. The bottom chamber contained Colo205 cells or 
30 ng/ml of EGF (R&D) or 30 ng/ml of IGF-1 (R&D). Cells on the top surface of the 
membrane were removed using a cotton swab and cells on the underside of the 
membranes were fixed with 4% PFA, stained with 0.2% crystal violet and counted in 5 
independent microscopic fields at a 20-fold magnification. Experiments were performed in 
triplicates. 
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2.2.10 Osteogenic differentiation of mouse MSCs 
 
MSCs were grown to 90-100% confluence in 24-well-plates and the culture medium was 
then replaced with osteogenic medium (α-MEM supplemented with 15% FBS plus 1% 
Penicillin/Streptomycin, 100 nM dexamethasone, 50 μg/ml ascorbate-2- phosphate, and 
10 mM beta-glycerol phosphate). The medium was changed every 2- 3 days. Osteogenic 
differentiation was assessed by Alizarin Red staining 21 days after initial osteogenic 
induction. In brief, cells were washed with PBS and allowed to dry for 5 - 10 min. Next, 
cells were fixed with 50% ethanol for 20 min. The fixed cells were then stained with 1% 
Alizarin red (Roth) at pH 6.4 for 30 min under continuous shaking. Finally, cells were 
rinsed 3 times with H2O, and transmitted light pictures were taken. As a negative control, 
cells grown in culture medium for 21 days were used.  
 
2.2.11 Adipogenic differentiation of mouse MSCs 
 
MSCs were grown to confluence on Permanox 4-well chamber slides (Thermo Scientific). 
Adipogenic differentiation medium, composed of α-MEM supplemented with 15% FCS 
plus 1% Penicillin/Streptomycin, 1 μM dexamethasone, 500 μM IBMX, 10 μg/ml human 
insulin and 100 μM indomethacin, was added and changed every 2-3 days. 12 days after 
initial adipogenic induction, cells were washed with PBS and fixed for 10 min in 4% 
Histofix (Roth). Next, cells were rinsed once with H2O and incubated in 60% isopropanol 
for 5 min. Subsequently, the cells were incubated for 10 min with Oil Red O. Finally, the 
cells were washed once with 60% isopropanol followed by H2O. Nuclei were 
counterstained with hemalaun. As a negative control, cells grown in culture medium for 12 
days were used. 
 
2.2.12 Immunofluorescence and microscopy 
 
MSCs were seeded on glass coverslips and incubated for 3 h at 37 °C. Then, coverslips 
were washed with PBS containing CaCl2/MgCl2, fixed for 10 min with 4% PFA and 
permeabilized with PBS containing 0.1% Triton X-100 for 5 min. The blocking step was 
performed by incubating the cells with 5% FCS in PBS for 30 min at room temperature. 
Next, cells were washed and incubated with primary antibody and DAPI (1 μg/ml) diluted 
in blocking buffer for 2 h, followed by washing steps with PBS-T. When required, 
incubation with secondary antibody, diluted in blocking buffer, was performed for 1 h. 
Coverslips were mounted in Fluoromount G (Southern Biotechnology) and analyzed with 
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the Spinning Disc using 488 nm, 543 nm and 633 nm excitation and a 20x/0.8 DIC 
objective lens. Images were processed with ZEN software. 
 
2.2.13 Flow Cytometry 
 
2.2.13.1 Propidium iodide staining 
After co-culture of MSCs and Colo205, as described in paragraph 2.2.8, the medium from 
each well was collected in a falcon tube. Then, cells were trypsinized and added to the 
respective culture medium. After centrifugation (5 min, 500 g), the supernatant was 
removed, the cell pellet resuspended in 100 μl of PBA and transferred in a 96-well plate. 
Next, PI (10 μg/ml) was added to the cells and incubated for 5 min, followed by flow 
cytometry analysis of the stained cells. 
 
2.2.13.2 Cleaved caspase 3 intracellular staining 
 
Colo205 (80.000 cells/well) were seeded in the bottom of a transwell plate (Costar) in 
RPMI-1640 medium (10% FCS) and incubated at 37 °C overnight. Then, medium was 
removed and after washing with PBS, changed with alpha-MEM medium with 10% FBS. 
Bortezomib (250 ng/ml) was added into the culture medium and incubated at 37 °C for 30 
min in order to sensitize the cells to TRAIL-induced apoptosis. Next, into the upper 
chamber of the transwell 16.000 cells for each MSC line, wild type (wt), clone #A1, clone 
#B12 or Mock, were seeded. After 16 h of incubation at 37°C, the transwell was removed 
and the culture medium was transferred in a falcon tube. Colo205 from the lower chamber 
were trypsinized, added to the respective culture medium and after centrifugation (5 min, 
3000 g), cell pellet was resuspended in 100 μl of PFA (4%) and transferred into a 96-well 
plate. After 10 min of fixation with PFA at room temperature, 2 washing steps with PBS 
(150 μl/well) and subsequent centrifugation (5 min, 1500 rpm) were performed. Next, 
permeabilization was achieved by incubation of cells for 10 min at RT with 
permeabilization buffer (0,1% Triton in PBA). Then, primary antibody (dilution 1:1500 in 
permeabilization buffer) was added and incubated for 1 h at RT with the cells. After two 
washing steps with PBA, as described above, secondary antibody (anti-rabbit-FITC) was 
incubated with cells for 45 min at RT (dilution 1:80 in permeabilization buffer). Finally, after 
two additional washing steps, cells were resuspended in 200 μl/well of PBA and analyzed 
by flow cytometry. 
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2.2.13.3 Expression of surface markers on cell lines 
 
In order to analyze the expression of surface markers, the cells of interest (MSCs, Caco2, 
Colo205, HCT116, LoVo) were seeded in a U-bottom 96-well plate (150.000 cell/well) and 
incubated 1 h at 4 °C with the specific primary antibody (Table 10). After 3 washing steps 
with 200 μl/well PBA, followed by centrifugation (5.000 g, 5 min, 4 °C), cells were 
incubated with the secondary antibody, when necessary, for 2 h at 4 °C. Otherwise, after 
the washing steps, cells were immediately resuspended in 150 μl/well PBA and analyzed 
by flow cytometry. The respective Isotypes antibodies, for the primary antibody directly 
conjugated, or the secondary antibodies alone were used as controls. 
 
2.2.13.4 Binding assay of fusion proteins 
 
Cells (Colo205, Caco2, HCT116) were seeded in U-bottom 96-well plate and incubated 
for 1 h at 4 °C, either with scFv proteins (scFvCD133, scFvLGR5) or with the fusion proteins 
(DbCD133-scTRAIL and DbCD133-scTRAIL), in both cases using a titration 1:3 for each 
protein. After three washing steps with 200 μl/well PBA, as above, cells were incubated for 
2 h at 4 °C with the secondary antibody, respectively anti-His-PE for scFv proteins or anti-
FLAG-PE for the recombinant proteins. Subsequently, 3 additional washing steps with 
PBA were performed, then the cells were resuspended in 150 μl/well PBA and 
immediately analyzed by flow cytometry. For detection control, only PE-conjugated anti-
His or anti-FLAG antibodies were incubated with the cells. 
 
2.2.14 Enzyme-linked immunosorbent assay (ELISA)  
 
In order to determine the amount of DbEGFR-scTRAIL secreted by MSCs in the culture 
medium or in the serum blood in vivo (2.2.15.1), ELISA assays were performed using the 
kit OptEIA™ human TRAIL ELISA Set (BD), according to the manufacturer’s instruction. 
Briefly, the ELISA plate was coated with 100 μl/well of capture antibody and incubated 
overnight at 4 °C. Then, after 3 washing steps with ELISA washing solution (0.05 % (v/v) 
Tween20 in 1x PBS), 200 μl/well of ELISA blocking solution (2 % (w/v) dry milk in PBS) 
were added and incubated for 1 h at RT. Next, a titration of standard TRAIL protein (start 
from 2 ng/ml, titration 1:3) and serial dilutions of MSC supernatant or serum blood (dilution 
1:20), in duplicate, were added and incubated 2 h at RT. After 5 washing steps, working 
detector solution (100 μl/well) was incubated 1 h at RT. Next, additional 7 washing steps 
were performed as above and subsequently 100μl/well of ELISA developing solution (0.1 
mg/ml TMB, 100 mM sodium acetate buffer pH 6.0; 0.006 % H2O2) was added and 
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incubated 30 min in the dark at RT. Finally, the enzymatic reaction was stopped by adding 
50 μl/well of 1 M H2SO4 and the absorbance at 450 nm was measured in an ELISA 
reader. 
 
2.2.15 In vivo studies 
 
All studies with experimental animals were performed according to federal guidelines. 
Mice were at least 9 weeks old at the beginning of the experiments and were allowed to 
acclimate for at least two weeks in our animal facilities. All experiments were conducted 
using female nude NMRI mice obtained from Charles River Laboratories. 
 
2.2.15.1 DbαEGFR-scTRAIL serum concentration 
 
Two groups, each composed by five mice, were injected with MSCs expressing DbαEGFR-
scTRAIL or mock-transfected MSCs. In one case subcutaneous injections were performed 
using 4 x 106 cells/injection. For the second group, MSCs were intravenously 
administrated (1 x 106 cell/injection). In both cases 100 μl PBS were used as final volume 
for each injection, in combination with 100 IU/ml of heparin (Rapp et al., 2015), in order to 
avoid cell clotting. Next, blood samples were collected from the tail vain 1, 3, 7, 14 and 21 
days after the MSC injections and stored at -20 °C. Finally, after centrifugation (10.000 g, 
10 min, 4 °C) clotting cells were removed and serum levels of DbEGFR-scTRAIL were 
measured performing a TRAIL ELISA assay as described in 2.2.14. 
 
2.2.15.2 Antitumor activity 
 
Female nude NMRI mice were subcutaneously injected with 3 x 106 Colo205 cells, in a 
total volume of 100 μl PBS, at both dorsal sides left and right. The treatments with MSCs, 
expressing DbEGFR-scTRAIL, were started when the tumor volumes reached about 100 
mm³. In particular, 4 x 106 MSCs were resuspended in 100 μl PBS mixed with 100 IU/ml 
of Heparin and then peritumorally injected (p.t.). During the injections of all cell lines, mice 
were anesthetized with isoflurane. The Colo205-bearing mice received three peritumoral 
injections of MSCs at day 10, 17, 27. While, 5 μg of bortezomib dissolved in 100 μl PBS 
were injected i.p every second day, starting from day 11 until day 31. Mice in the control 
groups received either 100 μl PBS i.p injected or MSCs. The mock cell line was p.t 
injected in combination with bortezomib administrated i.p every other day. Tumor growth 
was monitored with a caliper and tumor volume was determined as follows (L, longitudinal 
diameter of tumor; W, transverse diameter of tumor):    Tumor volume = (L * W2) / 2 
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2.2.15.3 ALT assay 
 
Nude mice received tumor treatments as described above (2.2.15.2). At day 31, blood 
samples were collected from the tail vain and after centrifugation (10.000 g, 10 min, 4 °C), 
the serum fractions were obtained and stored at -20 °C. The alanine transaminase (ALT) 
activity was analyzed by an enzymatic assay, according to the manufacturer’s instruction. 
 
2.2.16 Statistical analysis 
 
All values are expressed as means ± SEM (Standard Error of the Mean) while for the 
analysis of the in vivo studies the 95 % confidential interval (95 % CI) was used and the 
survival rate was measured using a log-rank test based on Kaplan-Meier method.  
Significances, for each experiment, were calculated with GraphPad prism one-way Anova 
with Tukey’s post-test. In particular: * represents a p-value < 0.05, ** p-value < 0.01 and 
*** p-value < 0.001. 
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3 Results 
 
In the first part of this study, two novel scFv-scTRAIL fusion proteins selectively targeting 
the cancer stem markers CD133 and LGR5 were generated. In fact, in the last several 
years evidence suggested the idea that the driving force behind tumor growth resides in 
the CSCs, which seem to be also responsible for metastasis formation and tumor relapse 
after therapy and which are resistant to conventional chemotherapy (Huang et al., 2008). 
For these reasons I investigated whether a selective targeting of optimized engineered 
variants of TRAIL to cancer cells, expressing these CSC markers, could be a new 
therapeutic approach.   
 
3.1 Db-scTRAIL fusion proteins targeting CSC markers: CD133 and 
LGR5 
 
3.1.1 Generation of humanized scFvαCD133 and scFvαLGR5 
 
The first step for the generation of scFv-scTRAIL fusion proteins was the production of 
specific humanized scFv fragments against CD133 or LGR5, scFvαCD133 and scFvαLGR5, 
respectively. For this purpose, from published sequences of CD133 and LGR5 specific 
antibodies, humanized scFvαCD133 and scFvαLGR5 fragments were generated, produced 
(2.2.5.3) and purified by IMAC using the His tag. The analysis of the integrity of both scFv 
fragments was performed by SDS page, which showed a single band at the expected 
molecular mass, around 30 kDa for scFvαCD133 and 28 kDa for scFvαLGR5, both under 
reducing and non-reducing conditions (Fig. 6).  
 
 
Figure 6: SDS-PAGE analysis of humanized scFvαCD133 and scFvαLGR5  
SDS-PAGE analysis of the purified scFvαCD133 and scFvαLGR5 proteins, under reducing (R) and non-reducing 
(N.R) conditions. 5 μg of purified protein was loaded for each sample Mk, protein standard marker. 
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Subsequently, the expression of both CSCs markers, CD133 and LGR5, was analyzed by 
flow cytometry (2.2.13.3) on four different colon cancer cell lines: Caco2, Colo205, 
HCT116 and LoVo. For CD133, only Colo205 cells were almost negative, while all the 
other cell lines were positive with the highest expression observed on Caco2 cells (Fig.7). 
Concerning LGR5, all cell lines were completely negative for this marker, except for LoVo 
cells that showed a significant surface expression (Fig 7). The absence of LGR5 
expression on three colon cancer cell lines Caco2, Colo205 and HCT116, could be 
explained by the fact that the expression of this marker is restricted only at the base of the 
crypts and not in the entire intestinal tissue (Barker et al., 2007).  
 
 
 
 
 
Figure 7: Surface expression of CD133 and LGR5 on colon cancer cell lines 
Flow cytometry analysis of CD133 and LGR5 expression (red line) on colon cancer cell lines Caco2, Colo205, 
HCT116 and LoVo. Unstained cells were used as negative control (black line). Y axis: number of events 
analyzed. Representative experiment out of 4 independent analyses.  
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According to the results of CSCs marker surface expression, HCT116 and LoVo cells 
were chosen for further investigations of scFv or fusion proteins for CD133 and LGR5, 
respectively. These two cell lines were used to perform a quantitative binding study by 
flow cytometry for both scFv proteins on the respective cell line. Data are shown as mean 
fluorescence intensity (MFI) and the concentration of half-maximum binding (EC50) was 
calculated. Dose response relationship revealed for both cell lines saturation binding and 
EC50 values  in the low nM range with an EC50 of 4,7 nM for scFvαCD133 and 5,8 nM for 
scFvαLGR5 (Fig. 8). As negative control Colo205 cells, which do not express both markers, 
were analyzed. No binding was detected in this cell lines for both scFv proteins (data not 
shown). 
 
 
 
 
Figure 8: Binding assay of scFvαCD133 and scFvαLGR5 on colon cancer cell lines 
Analysis of dose-response relationship of: (A) scFvαCD133 binding to HCT116 cells and (B) scFvαLGR5 binding to 
LoVo cells. All proteins were detected, by flow cytometry, via FITC-conjugated anti His-tag antibody and the 
concentration of half-maximum binding (EC50) was measured (mean ± S.E.M., n=4). 
 
 
3.1.2 Fusion proteins: DbαCD133-scTRAIL and DbαLGR5-scTRAIL 
 
The TRAIL fusion proteins were generated by fusing the humanized scFv fragments 
directed against CD133 or LGR5 to the N-terminus of human single-chain TRAIL 
(scTRAIL) comprised of three domains of the extracellular part of wild type TRAIL (aa 
118-281) connected via short linkers (Siegemund et al., 2012). The dimerization of the 
scFv-scTRAIL chain into a functional diabody was accomplished by a short glycine 
peptide linker (GGG) between VH (variable domain of immunoglobulin heavy chain) and 
VL (variable domain of immunoglobulin light chain), as described by Holliger et al., 1993. 
The schematic illustration of the fusion proteins is shown in figure 9. 
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Figure 9 Schematic illustration of the fusion proteins: DbαCD133-scTRAIL and DbαLGR5-scTRAIL 
A Schematic illustration of the scFv-scTRAIL fusion proteins. (A) DbαCD133-scTRAIL was generated by fusing 
the scFvαCD133, composed by VH and VL (show in orange and light orange) with the N-terminus of scTRAIL, 
comprised of three extracellular TRAIL domains (show in green). (B) For the generation of DbαLGR-scTRAIL, 
the scFvαLGR5 fragment, comprising VH and VL (show in blue and light blue) connected by a short peptide linker 
(GGG), was fused to the N-terminus of scTRAIL comprised of three extracellular TRAIL domains (show in 
green). L: VH leader; F: FLAG tag; H: His tag. 
 
 
Both fusion proteins, DbαCD133-scTRAIL and DbαLGR5-scTRAIL, were produced in stably 
transfected HEK293 cells (2.2.5.2) and purified from serum free cell culture supernatant 
by FLAG tag (2.2.5.4). The integrity of the purified fusion proteins was analyzed by SDS 
PAGE, immunoblotting as well as size exclusion chromatography (SEC) (Fig. 10). Both 
fusion proteins showed, in SDS PAGE and immunoblotting analysis, a single band 
matching the calculated molecular mass values of 83 kDa for DbαCD133-scTRAIL and 85 
kDa for DbαLGR5-scTRAIL (Fig. 10A, 10B). The size exclusion chromatography confirmed 
the correct assembly into dimeric molecules under native conditions, for both fusion 
proteins (Fig. 10C). In particular, DbαLGR5-scTRAIL was eluted in a single peak at an 
apparent molecular mass of approximately 170 kDa, while the fusion protein DbαCD133-
scTRAIL showed a major peak at the same apparent molecular mass of 170 kDa and a 
higher molecular weight fraction probably representing tetrameric assembly or other 
aggregated forms. 
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Figure 10 Biochemical analyses of DbαCD133-scTRAIL and DbαLGR5-scTRAIL fusion proteins 
Purified DbαLGR5-scTRAIL (line 1) and DbαCD133-scTRAIL (line 2) fusion proteins were analyzed by: (A) 
reducing SDS PAGE, 5 μg for each protein; (B) immunoblotting against antibody anti FLAG, loaded 1 μg for 
each protein and (C) size exclusion chromatography. Thyroglobulin (669 kDa), β-amylase (200 kDa), bovine 
serum albumin (66 kDa), carbonic anhydrase (29 kDa) and FLAG peptide (1 kDa) were used as standard 
proteins. Mk protein standard marker. 
 
 
Although the biochemical analyses confirmed integrity and mostly correct dimeric 
assembly for both fusion proteins, the yields were very low: 0,3 mg/L for DbαCD133-scTRAIL 
and 0,4 mg/L for DbαLGR5-scTRAIL. In order to overcome this problem and to increase the 
productivity, different experimental approaches were tested. The first one was lowering 
the culture temperature during HEK293 cultivation, from 37 °C to 32 °C, which enhances 
protein expression, as described by Chi-Yen et al. 2015. Unfortunately, this method was 
not successful with these constructs, in fact HEK293 cells did not show significant 
differences in productivity at 32°C, in comparison with 37°C, for both fusion proteins (data 
not shown). Then, giving the fact that stably transfected HEK293 represent a pool of 
transfected cells that likely show large cell selective differences in expression of the 
transgene, a screening for stable single producer clones was performed applying the 
limiting dilution method. For this, a cell density of 1 cell/well was used to seed HEK293 
 Results        
 
 
  
64 
 
  
cells after transfection, with either DbαCD133-scTRAIL or DbαLGR5-scTRAIL (2.2.4). Six 96-
well plates for each fusion protein were used for the selection and after about two weeks 
of cultivation under selective pressure of the antibiotic G418, a dot blot assay was 
performed using culture medium collected from each well (Supplementary figure S1). 
According to the Dot Blot results the best single clones, nine and six for DbαCD133-scTRAIL 
and DbαLGR5-scTRAIL, respectively, were selected and expanded in vitro. Next, the 
productivity was analyzed using an aliquot of cell free culture supernatant for each single 
clone, with the same seeding cell density, and verified by immunoblotting using an anti- 
FLAG antibody (Fig. 11).  
 
 
 
Figure 11 Single clone selection for DbαCD133-scTRAIL and DbαLGR5-scTRAIL 
Immunoblotting of cell free culture supernatant from (A), nine single clones of DbαCD133-scTRAIL and (B), six 
single clones of DbαLGR5-scTRAIL. 75 μl of cell free culture supernatant, for each line, were loaded and 
analyzed using an antibody against FLAG. Culture supernatants from DbαCD133-scTRAIL and DbαLGR5-scTRAIL 
pools cell lines were used as control. Mk protein standard marker. 
 
 
Given the results of the immunoblotting assays, the best  clones were chosen and 
expanded for further investigations. In particular, for DbαCD133-scTRAIL the clone A1/G5 
was selected and named #DbαCD133-scTRAIL, while for the fusion protein DbαLGR5-scTRAIL 
the clone G2/G3 showed the highest productivity and named #DbαLGR5-scTRAIL. 
Subsequently, a biochemical analysis of the fusion proteins expressed and purified from 
each single clone was performed, including SDS PAGE, immunoblotting and size 
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exclusion chromatography (Fig. 12).The SDS PAGE and the immunoblotting revealed a 
single band matching the calculated molecular mass values for both fusion proteins: 83 
kDa for #DbαCD133-scTRAIL and 85 kDa for #DbαLGR5-scTRAIL (Fig. 12A, 12B). In addition, 
the size exclusion chromatography confirmed the protein integrity and tendency to form 
dimeric molecules (Fig. 12C). It showed, in fact, for the fusion protein #DbαCD133-scTRAIL a 
major peak at an apparent molecular mass of approximately 170 kDa, while the #DbαLGR5-
scTRAIL fusion protein was eluted as a single peak at the same apparent molecular mass 
(~170 kDa), indicating a dominant and exclusive dimeric composition for the former and 
latter, respectively. Finally, the clone selection strategy was also successful concerning 
the productivity, showing slightly increased yields, in comparison to the pool. The protein 
production was enhanced ~1,6 fold for #DbαCD133-scTRAIL (yield: 0,5 mg/L) and ~ 2,2 fold 
for #DbαLGR5-scTRAIL (yield 0,9 mg/L). 
 
 
 
Figure 12 Biochemical analysis of purified fusion proteins from single clones: #DbαCD133-scTRAIL and 
#DbαLGR5-scTRAIL 
Purified #DbαCD133-scTRAIL (line 1) and #DbαLGR5-scTRAIL (line 2) fusion proteins from single clones (A1/G5 
and G2/G3 respectively) were analyzed by: (A) reducing SDS PAGE, 2 μg for each protein; (B) 
immunoblotting against antibody anti FLAG, loaded 1 μg for each protein and (C) size exclusion 
chromatography. Thyroglobulin (669 kDa), β-amylase (200 kDa), bovine serum albumin (66 kDa) and carbonic 
anhydrase (29 kDa) and FLAG peptide (1 kDa) were used as standard proteins. Mk protein standard marker. 
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3.1.3 In vitro bioactivity of #DbαCD133-scTRAIL and #DbαLGR5- 
scTRAIL 
 
Purified fusion proteins were investigated for their binding functionality by flow cytometry 
on appropriate target positive cell lines and half-maximum binding (EC50) was calculated 
from dose response curves. As expected, the purified fusion proteins showed binding to 
their respective target cell line in the low nM range with an EC50 of 4,6 nM for the fusion 
protein targeting CD133 and 6,1 nM for #DbαLGR5-scTRAIL (Fig. 13). Again, no binding 
was detectable on Colo205 cells, lacking these CSC markers (data not shown). 
 
 
Figure 13: Binding assay of #DbαCD133-scTRAIL and #DbαLGR5-scTRAIL on colon cancer cell lines 
Analysis of dose-response relationship of: (A) #DbαCD133-scTRAIL binding to HCT116 cells and (B) #DbαLGR5-
scTRAIL binding to LoVo cells. All proteins were detected, by flow cytometry, via PE-conjugated anti FLAG-
tag antibody and the concentration of half-maximum binding (EC50) was measured (mean ± S.E.M., n=3). 
 
 
Next, in order to investigate the bioactivity of the fusion proteins, TRAIL-mediated 
induction of cell death was analyzed on CD133-expressing HCT116 cell line and on LoVo 
cells which are positive for LGR5 expression. The cell death induction assays were 
performed in the presence or absence of two different sensitizers. The proteasome 
inhibitor bortezomib was used for HCT116 cells, while Smac mimetic was applied for 
LoVo cells, due to the fact that this cell line showed almost complete resistance to BZB 
activity (Supplementary figure S2). Both fusion proteins were capable to induce cell death, 
on the respective cell line, in the absence of sensitizers over the tested concentration 
range from 1 pM to 10 nM. In particular, for #DbαCD133-scTRAIL an EC50 value on HCT166 
cells of 100 pM was revealed. Similarly, #DbαLGR5-scTRAIL showed an EC50 value of 140 
pM on LoVo cells. The cell death inducing effect of both TRAIL fusion proteins was further 
increased in the presence of the respective sensitizers (Fig. 14). In fact, #DbαCD133-
scTRAIL in combination with bortezomib (250 ng/ml) showed an EC50 value of 24 pM, 
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while for #DbαLGR5-scTRAIL, in the presence of Smac mimetic (0,1 μM), the EC50 value 
was around 38 pM. These data demonstrate that both TRAIL fusion proteins generated 
were functional and active in apoptosis induction in a pM range. Furthermore, cell death 
induction is even stronger in combination with the respective sensitizers, resulting in a ~4-
fold increase in activity for both fusion proteins.  
 
 
 
Figure 14 Cell death induction assay of #DbαCD133-scTRAIL and #DbαLGR5-scTRAIL on CRC cell lines in 
the presence or absence of sensitizers in vitro 
(A) HCT166 cells were sensitized with 250 ng/ml of bortezomib (BZB) and treated with serial dilutions (1:3) of 
#DbαCD133-scTRAIL (starting from 10 nM). (B) LoVo cells were sensitized with Smac Mimetic (SM= 0,1 µM) 
and treated in combination with a titration 1:3 of the fusion protein #DbαLGR5-scTRAIL (starting concentration: 
10 nM). After 18 h, cell density was determined using crystal violet staining and data were normalized using 
bortezomib-treated cells or Smac mimetic-treated cells as control (mean ± S.E.M., n=4). 
 
 
Subsequently, with the aim of verifying the scFv-receptor targeting capacity of #DbαCD133-
scTRAIL and #DbαLGR5-scTRAIL cell death induction by both fusion proteins was 
compared with the TRAIL-mediated apoptosis induction of a non-targeting fusion protein 
Fc-scTRAIL. This latter resembles the hexameric configuration of the Db-scTRAIL 
molecule, but lacks the specific antigen (CSC marker in this case) binding activity (Fc-
scTRAIL protein kindly provided by Dr. Martin Siegemund). As in the experiments above, 
cell death induction was performed in the presence of the respective sensitizers for the 
two different cell lines. Surprisingly, the EC50 values of non-targeting Fc-scTRAIL were 
found to be comparable, without any significant differences, with those of #DbαCD133-
scTRAIL and #DbαLGR5-scTRAIL on HCT116 and LoVo cell line, respectively (Fig. 15). In 
particular, #DbαCD133-scTRAIL showed an EC50 value of 23 pM and Fc-scTRAIL 25 pM on 
HCT116 cells, while for #DbαLGR5-scTRAIL the EC50 value was 34 pM and 38 pM for non-
targeting Fc-scTRAIL on LoVo cell line.  
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Figure 15 In vitro cell death induction assay of #DbαCD133-scTRAIL and #DbαLGR5-scTRAIL fusion 
proteins in comparison with the non-targeting protein Fc-scTRAIL 
(A) HCT166 cells were sensitized with 250 ng/ml of bortezomib (BZB) and treated with a serial dilutions (1:3) 
of #DbαCD133-scTRAIL or Fc-scTRAIL protein (starting from 10 nM). (B) LoVo cells were sensitized with Smac 
mimetic (SM= 0,1 µM) and treated in combination with a titration (1:3) of #DbαLGR5-scTRAIL or the non-
targeting protein Fc-scTRAIL (starting concentration: 10 nM). After 18 h, cell density was determined using 
crystal violet staining and data were normalized using bortezomib-treated cells or Smac mimetic-treated cells 
as control (mean ± S.E.M., n=4). 
 
 
Additionally, in order to confirm that the fusion proteins did not improve the TRAIL activity 
upon binding to the target antigen, competition assays with the respective scFv proteins 
were performed. In fact, binding conditions under competition with scFv fragments should 
correspond to those of a scTRAIL protein without antigen targeting. In detail, three 
different concentrations of the fusion proteins, 1 nM, 0,5 nM and 0,01 nM, were incubated 
with HCT116 and LoVo cells in the presence or absence of a 100-fold molar excess of 
either scFvαCD133 or scFvαLGR5 (Fig. 16). The analysis of the cell viability did not show a 
significant difference concerning cell death induction between TRAIL fusion proteins alone 
(#DbαCD133-scTRAIL and #DbαLGR5-scTRAIL) and in combination with the excess of the 
respective scFv fragments, for all protein concentrations tested. This confirmed the 
absence of an increased bioactivity of CSC targeted TRAIL fusion proteins comprising 
these two specific scFv targeting domains, in comparison with non-targeted TRAIL in this 
experimental setting. 
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Figure 16 In vitro bioactivity of #DbαCD133-scTRAIL and #DbαLGR5-scTRAIL fusion proteins in the 
presence or absence of competition with scFvαCD133 and scFvαLGR5, respectively  
The fusion proteins were added at concentrations 1 nM, 0,5 nM and 0,01 nM to (A) HCT116 cells for 
#DbαCD133-scTRAIL or (B) to LoVo cells for #DbαLGR5-scTRAIL. The scFv proteins were incubated, using a 100-
fold molar excess, with the cells 30 min before the respective fusion proteins. After 18 h, cell viability was 
determined using crystal violet staining (mean ± S.E.M., n=3). 
 
 
In conclusion, the Db-scTRAIL fusion proteins targeting the CSCs markers CD133 and 
LGR5, were successfully expressed and produced in the correct dimeric assembly, as 
confirmed by SEC analysis. Concerning the bioactivity, both constructs, #DbαCD133-
scTRAIL and #DbαLGR5-scTRAIL, exhibited significant TRAIL-mediated apoptosis induction 
in vitro on the respective cell lines. The cell death induction was even stronger when the 
fusion proteins were used in combination with appropriate sensitizers, resulting in a ~4 
fold increase potency .  
Nevertheless, with the particular cell lines studied in vitro, the fusion proteins #DbαCD133-
scTRAIL and #DbαLGR5-scTRAIL, despite proven binding to their cognate targets, revealed 
no positive effect of CSC marker binding on induction of apoptosis when compared to 
non-targeted TRAIL variants.  
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3.2 MSCs as delivery vector for DbαEGFR-scTRAIL expression in 
situ 
 
In the second part of this study I investigated the potential use of MSCs, as an in situ cell 
based delivery system for the expression of a tumor targeting TRAIL fusion protein, both 
in vitro and in vivo. Toward this aim, a murine MSC cell line, previously generated at the 
Institute of Cell Biology and Immunology in Stuttgart (Raeth et al., 2013) was used as a 
model cell and an activity optimized Db-scTRAIL fusion protein targeting EGFR (DbαEGFR-
scTRAIL) (Siegemund et al., 2012) was used as a model substance.  
 
 
3.2.1 MSCs insensitivity to DbαEGFR-scTRAIL  
 
Several studies reported a significant enhancement of apoptotis on colon cancer cells 
using combined treatment based on e.g. antibodies and sensitizers, such as bortezomib 
(Zhu et al., 2005 and Cacan et al., 2015) and Smac mimetic (Lu et al., 2011 and Roesler 
et al., 2016).   
As a prerequisite to study the use of MSCs for a cell based therapy with TRAIL fusion 
proteins, apoptosis sensitivity of MSCs in comparison to the Colo205 CRC to be used in 
this tumor model needed to be established. Because the intension for subsequent in vivo 
studies was to investigate combinatorial activity of TRAIL fusion protein with apoptosis 
sensitizers (bortezomib and smac mimetic), a potential superior apoptotic effect of 
combined treatment was studied. The combined treatment produced a strong 
enhancement of cell death induction on Colo205 cells, for both sensitizers, resulting in a 
~9-fold increase of TRAIL-mediated apoptosis induction for BZB and ~4-fold for 0,1 µM 
SM and ~1,4-fold for 0,01 µM. (EC50 values: DbαEGFR-scTRAIL 19 pM; DbαEGFR-scTRAIL + 
BZB 2,2 pM; DbαEGFR-scTRAIL + SM 0,1 µM 4,2 pM and DbαEGFR-scTRAIL + SM 0,01µM 
13 pM) (Fig. 17). 
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Figure 17 Cell death induction assay of DbαEGFR-scTRAIL on Colo 205 in the presence of sensitizers 
Colo205 were sensitized with 250 ng/ml of bortezomib (BZB) (A) or with Smac Mimetic (SM), using two 
concentrations 0,1 µM and 0,01 µM (B), in combination with serial dilutions (titration 1:3) of DbαEGFR-scTRAIL. 
After 18 h, cell density was determined using crystal violet staining and data were normalized using 
bortezomib-treated cells or Smac mimetic-treated cells as control (mean ± S.E.M., n=3). 
 
 
Next, In order to assess the suitability of MSCs as vehicle for the expression of DbαEGFR-
scTRAIL, the sensitivity of this stem cell line to Db-scTRAIL activity was analyzed under 
the same conditions of co-stimulation with apoptosis sensitizers (bortezomib and smac 
mimetic), as for the CRC line Colo205.   
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Figure 18 Cell death induction assay of DbαEGFR-scTRAIL on MSCs in the presence of sensitizers 
MSCs were sensitized with 250 ng/ml of bortezomib (BZB) (A) or with Smac mimetic (SM), using two 
concentrations 0,1µM and 0,01 µM (B), in combination with different concentrations of DbαEGFR-scTRAIL. After 
18 h, cell density was determined using  crystal violet staining and data were normalized using bortezomib-
treated cells or smac mimetic-treated cells as control (mean ± S.E.M., n=4). 
 
 
As shown in figure 18, MSCs were fully resistant to DbαEGFR-scTRAIL activity even in the 
presence of both sensitizers, under which conditions Colo205 cells were completely killed.   
Taking together these results confirmed that MSCs are potentially suitable cells for 
generation of a cell based in situ delivery system of highly active TRAIL variants for 
colorectal cancer treatment. 
 
3.2.2 Transient transfection of MSCs with DbαEGFR-scTRAIL 
 
In order to express DbαEGFR-scTRAIL in the murine MSC model cell, different methods 
were tested. Although several specific kits for stem cells transfection are commercially 
available, the best results in terms of cell surviving and transfection efficiency were 
obtained using the Polyethyleneimine (PEI) method.  
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In a first step, MSCs were transiently transfected with DbαEGFR-scTRAIL and the 
transfection efficiency was verified by ELISA, testing cell culture medium after different 
time points and through immunoblotting analysis of DbαEGFR-scTRAIL purified from culture 
medium (2.2.5.4). As shown in figure 19A, MSCs were able to secrete the soluble form of 
the TRAIL fusion protein, the production was monitored daily for five days, revealing a 
slight, but steady increase for the measured time period, indicative of gradual cessation of 
expression, yet product accumulation. Western blot of purified TRAIL protein from culture 
medium, after 5 days of cultivation, confirmed existence of a full length protein, with no 
evidence for major degradation products (Fig. 19B).  
 
 
 
 
 
Figure 19 Expression of DbαEGFR-scTRAIL secreted by MSCs after transient transfection 
(A) MSCs were transiently transfected (PEI) and the amount of soluble DbαEGFR-scTRAIL released in cell free 
culture medium was measured by ELISA, every 24 hours (mean ± S.E.M., n=3). (B) After 5 days of transient 
transfection DbαEGFR-scTRAIL secreted in cell medium was purified and analyzed by Western blotting using an 
antibody against TRAIL.  
 
 
In order to verify whether DbαEGFR-scTRAIL secreted by MSCs is active and functional for 
apoptosis induction, the cell culture medium was collected every 24 h for five days after 
transient transfection and tested. In particular, serial dilutions of the daily collected 
medium were prepared to treat Colo205 cells with or without the sensitizer bortezomib or 
in combination with a specific blocking anti TRAIL antibody (Ab anti TRAIL-2E5). After 18 
hours of treatment, the cell death induction was analyzed by crystal violet assay (Fig. 
20A). The latter revealed a strong cell viability reduction, in the presence of bortezomib, 
which is TRAIL dose-dependent evident from the amount of protein secreted daily, as 
shown by the ELISA assay (Fig. 20B). In fact, the strongest cell viability reduction, around 
85 %, was observed treating Colo205 cells with culture medium collected after one day of 
transfection, which represents the time point with the highest TRAIL productivity in 
transient transfection conditions. 
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Figure 20 Cell death induction assay of secreted DbαEGFR-scTRAIL on Colo 205 
(A) Colo205 cells were sensitized with bortezomib (BZB, 250 ng/ml) and treated with serial dilutions of daily 
collected MSCs medium (serial medium dilutions 1:3, 1:9, 1:27) with or without the presence of anti-TRAIL 
antibody (Ab anti TRAIL, 1 µg/ml). As control (CTR) Colo205 cells were cultivated only with RPMI medium. 
After 18 h, cell density was determined using crystal violet staining and data were normalized using 
bortezomib-treated cells as control (mean ± S.E.M., n=4). (B) MSCs were transiently transfected and the daily 
amount of soluble DbαEGFR-scTRAIL released in cell culture medium was measured by ELISA (mean ± S.E.M., 
n=3). 
 
 
Furthermore, a nearly complete block of cell death induction was obtained after treatment 
with the anti-TRAIL antibody, which specifically neutralizes TRAIL. This result confirmed, 
consequently, that the reduction in cell viability observed after combined treatments was 
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strictly TRAIL dependent. Of note, Colo205 did not undergo significant apoptotic cell death 
upon treatment without the sensitizer bortezomib as single agent. 
To further investigate the bioactivity of DbαEGFR-scTRAIL secreted by MSCs, co-culture 
experiments were performed. MSCs transiently transfected 24 h before (named 
MSC.TRAIL) were co-cultured with Colo205 cells for additional 24 hours, in the absence 
or presence of bortezomib. In this case, cell death was tested with Propidium iodide (PI) 
staining. As shown in figure 21, mixing of MSCs transiently transfected with colorectal 
cancer cells gave rise to a significant increase of cell death in combination with 
bortezomib as compared with the untransfected MSCs or with MSC.TRAIL without 
sensitizer, in accordance with the previous analysis. Moreover, the co-cultures seem to 
show induction of apoptosis in a TRAIL dose dependent manner, revealed by the fact that 
different ratios of MSCs and Colo205 cells (1:5 and 1:50), produced different levels of cell 
death. Of note, DbαEGFR-scTRAIL without the sensitizer did not show a significant cell 
death induction on Colo205 cells. 
These data demonstrated that transiently transfected MSCs are able to secrete a 
bioactive DbαEGFR-scTRAIL. 
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Figure 21 Analysis of cell death induction after co-culture of Colo 205 with MSCs  
(A) One day after transient transfection MSCs (MSC.TRAIL) were co-cultured with Colo205 cells (100.000 
cells) in the presence or absence of BZB (250 ng/ml) for additionally 24 h. Two different ratios of MSCs and 
Colo205 were tested, 1:5 and 1:50. Y axis: number of events analyzed.  (B)  The number of dead cells was 
quantified by PI staining. Colo205 alone were used as PI background signal and Colo205 treated with 
TritonX100 (10%) as positive cell death signal. 
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3.2.3 Establishment of stable transfected MSC lines 
 
Based on successful transient transfection of MSCs and production of Db-scTRAIL, it was 
next asked whether transfection can be established for stable production of this fusion 
protein under retention of their normal stem cell characteristics, i.e. differentiation potential 
according to the environmental context, to obtain a rational for potential in vivo application. 
So far, the majority of published studies are based on viral transfection, despite all the 
concerns about the safety of the viral system (Grisendi et al., 2014; Stuckey and Shah 
2013). In fact, only few studies had assessed non-viral transfection method for cell-based 
tumor treatment (Choi et al., 2011 and Hu et al., 2012), that could overcome some of the 
concerns related to this approach. For these reasons, in this thesis, I chose and tested a 
non-viral system to establish stable transfected MCS lines, expressing the antitumoral 
agent DbαEGFR-scTRAIL fusion protein, for colorectal cancer treatment. 
 
First, the sensitivity of MSCs to the selection drugs Zeocin (Zeo) and Geneticin (G418), 
was assessed. Ten different concentrations, up to 800 µg/ml, of both antibiotics were used 
to treat MSCs and after 7 days the cell viability was analyzed through crystal violet assay 
(Fig. 22).  
 
 
Figure 22 Analysis of MSCs sensitivity to zeocin and geneticin 
MSCs were treated with different concentrations of Zeocin (Zeo) or Geneticin (G418). After 7 days cell density 
was determined using crystal violet staining and data were normalized using untreated cells as control (mean 
± S.E.M., n=3). 
 
 
MSCs showed nearly complete resistance to zeocin activity, only 30% of cell death was 
observed, even at high concentration of the antibiotic. While geneticin induced a strong 
reduction of cell viability, around 90%, using a range of antibiotic dose between 300 µg/ml 
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and 800 µg/ml. Based on these results, 150 µg/ml and 250 µg/ml were chosen as subtoxic 
concentrations for the selection of stable cell lines: M2#1.TRAIL and M2#2.TRAIL which 
were transfected with EGFR-pCR3-Db-scTRAIL and selected respectively with 150 µg/ml 
and 250 µg/ml of G418. In addition, the corresponding mock cell lines (Mock#1, Mock#2) 
were generated using the pCR3 empty vector. All the cell lines, the vectors and the 
antibiotic concentrations used are listed in Table 18.  
 
 
 
Table 18: List of stable cell lines, vectors and antibiotic concentration used for MSC stable cell lines 
generation 
 
 
Next, the productivity of DbαEGFR-scTRAIL secreted by stable MSC lines was tested 
analyzing cell medium after 4 and 6 days of in vitro cultivation by TRAIL ELISA. The 
M2#2.TRAIL cell line revealed  higher productivity as compared to M2#1.TRAIL. As 
expected, no specific signal was detectable for the controls M2 untransfected and Mock 
cell lines (Fig. 23A). Co-culture of stable MSC lines with Colo205 as target for Db–
scTRAIL revealed strong reduction of cell viability only for the cell line M2#2.TRAIL in 
combination with the sensitizer (Fig. 23B). These results demonstrate that DbαEGFR-
scTRAIL secreted by stable cell line M2#2.TRAIL, is functional and can induce cell death 
in Colo205 cells. While for the other cell line, M2#1.TRAIL, despite detection of fusion 
protein by ELISA assay, no bioactivity was revealed from the same culture supernatants. 
This could have been due to a lower productivity of these stable cells, in accordance with 
the ELISA assay. 
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Figure 23 Analysis of productivity and bioactivity of stable transfected MSC lines 
(A) The amount of soluble DbαEGFR-scTRAIL released in the cell culture medium, by stable transfected MSC 
lines (Table 18), was measured by ELISA after 4 and 6 days of culture (mean ± S.E.M., n=4). (B) The 
bioactivity of the secreted DbαEGFR-scTRAIL was analyzed after 24 h of co-culture seeding different ratios of 
MSCs and Colo205 cells (ratios 1:5; 1:20 and 1:50). The co-cultures were treated in combination with BZB 
(250 ng/ml). Cell density was analyzed using crystal violet staining and data were normalized using Colo205 
cells treated only with BZB as control (mean ± S.E.M., n=4). 
 
Unfortunately, after long time of in vitro cultivation (passage 35) even the M2#2.TRAIL cell 
line progressively lost DbαEGFR-scTRAIL productivity and consequently its bioactivity (data 
not shown). This phenomenon can be explained by the fact that the selection process has 
generated a mixed population of drug resistant cells, with different levels of protein 
secretion, resulting in a heterogeneous pool of cells within the same cell line. In this 
context, during in vitro cultivation the different sub-populations, which compose one cell 
line, non-producer cells may have proliferation advantages and eventually overgrow the 
producer cells in such a mixed population.  
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3.2.4 Selection of stable MSC single clones 
 
Having shown that stable transfectants of Db-scTRAIL producing MSCs can, in principle, 
be established, in a next step, single clone selection was performed by limiting dilution in 
order to avoid the limitations observed using a pool of transfected cells. The method used 
in this study is based on limiting serial dilutions in multiwell plates, which allows growing 
and selection of resistant cells as single cell culture which should show equal features 
such as productivity. 
MSCs were transfected with DbαEGFR-scTRAIL and after overnight they were immediately 
plated, in multiwell plate, performing limiting dilutions (2.2.4) with a statistical density of 1 
cell/well (six 96-well plates). After 41 days of cultivation cell confluence of positive wells 
was around 70%. At this time point, secretion of the proteins into the culture medium was 
checked and protein concentration estimated semi-quantitatively through dot blot assay, 
as show in figure 24. 
 
  
 
Fig 24 Dot blot analysis of MSC single cell cultures 
After 41 days of single cell cultivation, culture medium from each well was analyzed by dot blot using a 
specific antibody against FLAG and 13 single clones were selected (red circles). The pool M2#2.TRAIL cell 
line was used as control (green squares). 
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According to the dot blot results thirteen single cell cultures, which showed the highest 
DbαEGFR-scTRAIL expression, were selected and expanded in vitro. Next, product 
concentration was quantitatively analyzed by ELISA after 3 days of cultivation, seeding 
the same number of cells (Fig. 25A). Surprisingly, only two of thirteen single clone cultures 
selected showed enhanced levels of proteins in comparison with untransfected cells and 
with the pool M2#2.TRAIL. The productivity of both best clones, named clone#A1 and 
clone#B12, was confirmed also by immunoblotting analyzing the purified TRAIL protein 
from culture medium (Fig. 25B). Additionally, the cell proliferation rates were tested 
showing comparable levels between the two clones and the untransfected or Mock cell 
lines during in vitro cultivation (Supplementary figure S3).  
 
 
 
Figure 25 Single clones selection  
(A) The 13 clones selected after the Dot Blot analysis were seeded (1x10
6
 cells) and cultured. After 3 days the 
amount of soluble DbαEGFR-scTRAIL released in culture media was measured by ELISA. MSCs untransfected 
(UNT) and the pool M2#2.TRAIL were used as controls (mean ± S.E.M., n=3). (B) After 5 days of cultivation 
DbαEGFR-scTRAIL secreted in cell media was purified and analyzed by western blotting for each cell line using 
an anti TRAIL antibody. 3μg of purified DbαEGFR-scTRAIL (CTR) was used as control. 
 
A possible reason to explain the discrepancy between the dot blot data, which revealed 13 
positives clones, and the ELISA assay is that in the first analysis signals detected were 
not adjusted to the cell number in each well. In fact, the dot blot was performed from 
supernatant directly after 41 days of cultivation. While, for the ELISA assay each cell line 
was plated using the same number of cells and the culture medium was collected and 
tested after 3 days.  
All further experiments were done using the two positive clones selected: clone#A1 and 
clone#B12. Both showed a cumulative secretion of DbαEGFR-scTRAIL up to 5 days of 
cultivation (Fig. 26A) which was maintained over time in vitro, even at late passages (p 
44) (data not shown). Next, the bioactivity of proteins secreted by the clones was 
investigated performing co-culture of Colo205 cells with clone#A1 or clone#B12 in 
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combination with bortezomib and/or anti-TRAIL antibody. After 24 h cell number was 
analyzed by crystal violet assay showing, for both clones, a strong reduction in 
combination with bortezomib (Fig. 26B). Similar results were obtained with pool 
M2#2.TRAIL cell line. Moreover in the presence of neutralizing TRAIL antibody a nearly 
complete rescue of cell number was observed. This confirmed that the reduction of cell 
viability on colon cancer cells is due to a specific TRAIL effect. 
 
 
 
 
Figure 26 Analysis of productivity and bioactivity of MSC single clones #A1 and #B12 
(A) The amount of soluble DbαEGFR-scTRAIL released in the culture medium, by stable transfected MSC cell 
line (MSC.Mock, clon#A1, clone #B12) and MSC untransfected (MSC unt), was measured by ELISA after 3 
and 5 days of culture (mean ± S.E.M., n=5). (B) The bioactivity of the secreted DbαEGFR-scTRAIL by clones 
was tested after 24 h of co-culture of MSC lines and Colo205 (ratios 1:5 and 1:50). The co-cultures were 
treated in combination with BZB (250 ng/ml) and or Antibody anti-TRAIL (Ab anti TRAIL; 1 µg/ml). Cell density 
was analyzed using crystal violet staining and data were normalized using Colo205 cells treated with BZB as 
control (mean ± S.E.M., n=3). 
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All the results concerning DbαEGFR-scTRAIL bioactivity were obtained performing standard 
cytotoxicity assays on Colo205 cells, using crystal violet staining as a read-out. In order to 
confirm that the observed reduction of cell number is due to an apoptotic process, cleaved 
caspase 3 levels were analyzed as a direct indicator of activation of apoptosis. In 
particular, a co-culture was performed using a double chamber system with a membrane 
allowing free exchange of soluble mediators. Colo205 cells were seeded in the bottom 
chamber and the DbαEGFR-scTRAIL producing clones #A1, #B12 or the Mock cells were 
seeded in the upper chamber. Cleaved caspase 3 levels in Colo205 cells were analyzed 
by flow cytometry after 18 h of co-culture. A strong increase of cleaved caspase 3 levels 
were found when Colo205 cells were exposed to either of the DbαEGFR-scTRAIL producing 
clones in combination with the sensitizer BZB, with mock transfected MSC serving as 
negative control. A weak signal was also noted upon incubation of Colo205 with sensitizer 
bortezomib only (Fig. 27). These data demonstrate that the strong reduction of cell 
number observed in the previous analyses is a specific effect of apoptotic pathway 
activation, induced by DbαEGFR-scTRAIL activity, in combination with BZB. 
 
 
Figure 27 Analysis of caspase 3 activation after co-culture of Colo 205 with MSC clones 
Colo205 cells were seeded in the lower chamber of a transwell (20.000 cells). After overnight cultivation the 
stable clones #A1, #B12 and the Mock cells were seeded in the upper chamber (80.000 cells) and BZB (250 
ng/ml) was added to the medium. After 18 h of treatment, Colo205 were collected, stained with the specific 
cleaved caspase 3 antibody (Asp 175) and analyzed by flow cytometry. (A) Y axis: number of events 
analyzed. (Db-scTRAIL sec: fusion protein secreted by MSCs) (mean ± S.E.M., n=4).  
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Next, the potential tumor homing ability of wild type and stably transfected MSCs was 
investigated performing in vitro migration assays as a surrogate indicator of directed 
migration. Even if the factors that mediate this process have yet to be completely clarified, 
several soluble factors have been reported to exert chemotactic effects on MSCs, 
including EGF and insulin-like growth factor 1 (IGF-1) (Ponte et al., 2007). In the present 
work, the ability of these two growth factors to promote MSCs migration was tested. As 
shown in figure 28, both growth factors induced a significant increase in cell migration in 
comparison with normal culture medium (Alpha-MEM + 0,5% FBS). Interestingly, both 
EGF and IGF-1 induced comparable effects in cell motility on untransfected MSC and all 
the stably transfected cell lines analyzed: clone #A1, clone#B12 and Mock. These results 
indicated that the stable transfection and the selection of these cells did not interfere with 
their migration ability, confirming their applicability as drug delivery system. In addition, 
instead of adding chemotactic factors, Colo205 cells were placed into the bottom wells, 
but no MSCs migration could be observed under these conditions, suggesting that 
Colo205 possibly lack production/secretion of suitable chemotactic factors for these MSC 
lines.  
 
 
 
Figure 28 Analysis of MSC’s migration ability 
MSCs untransfected, clone #A1, clone #B12 and Mock cells were seeded (15.000 cells) in medium containing 
0,5% FBS into the upper chamber of a transwell. The lower well contained: only medium (0,5% FBS); Colo 
205 (80.000 cells) or the following concentrations of soluble growth factors: EGF (30 ng/ml) and IGF-1 (30 
ng/ml). Cells that had migrated across the filter after 8 hours were fixed and stained. The number of migrated 
cells was determined by counting five independent microscopic fields (20-fold magnification) per filter. Data 
showed the mean of six independent experiments performed with duplicate filters (mean ± S.E.M., n=6). 
 
 
In summary, these in vitro data demonstrate that the established MSC clone derived cell 
lines are able to maintain over time during cultivation (up to passage 42) the production of 
the therapeutic protein, which exerts in vitro strong apoptotic activity on colon cancer cells 
in combination with BZB. 
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3.2.5 Characterization of MSC stable clones 
 
In order to investigate whether the stable clones selected maintain mesenchymal stem 
cell characteristics over time in vitro, the properties of these cells were analyzed at 
different passages. First of all the phenotype of MSCs lines was tested staining the cells 
with phalloidin to visualize the F-actin. All cell lines analyzed by fluorescence microscopy: 
MSCs untransfected, clone #A1, clone #B12 and Mock, displayed a typical spindle-
shaped phenotype as described for MSCs in literature (Dominici et al., 2006). 
Remarkably, the phenotype did not change during in vitro cultivation up to passage 42 
(Fig. 29). 
 
 
 
 
 
Figure 29 Phenotype of mesenchymal stem cell lines 
Mesenchymal phenotype for MSCs untransfected (MSCs unt), single clone #A1 (clone #A1), single  clone 
#B12 (clone #B12) and Mock (MSC.Mock) was analyzed at early (p 14), middle (p 25), and late (p 42) 
passages. Cells were stained with Alexa Fluor568-coupled phalloidin (red/orange). The nuclei were 
counterstained with DAPI (blue). Scale bar, 50 μm. 
 
 
Next, the expression of stem cell markers was investigated for all cell lines. In accordance 
with the International Society of Cellular Therapy (ISCT), all MSC lines analyzed were 
positive for CD9, CD44, CD71 and CD105 and lack the expression of CD14 and CD34, as 
show in figure 30. No differences between untransfected MSCs and the stably transfected 
cell lines were observed. Interestingly, the pattern of marker expression, including CD9, 
CD44, CD71 and CD105, was maintained from early passage (p 9) up to passage 42 
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(Supplementary figure S4). Additionally, these results obtained here with MSCs 
transfected with Db-scTRAIL are in accordance with other studies which described most 
of the markers also expressed by different murine MSCs lines (reviewed by Boxall and 
Jones 2012). 
 
 
 
 
 
Figure 30 Surface MSCs marker expression 
Analysis of surface markers expression: CD9, CD44, CD71, CD105, CD14 and CD34 on MSC lines at 
passage 25. Cells were stained with indicate antibodies and binding was analyzed by flow cytometry (red line). 
Unstained cells were used as negative control (black line). Y axis: number of events analyzed. Representative 
experiment out of 5 independent experiments performed. 
 
 
Nevertheless, the most important characteristic necessary to define MSCs is their 
multilineage differentiation capability. Towards this end, I verified by the standard 
differentiation assays their ability to differentiate into adipocytes and osteocytes. All MSCs 
lines showed, on one hand, the capability to generate lipid droplets which indicate a 
successful adipogenic differentiation (Fig. 31A). In rare cases a spontaneous adipogenic 
differentiation was observed, probably due to a high cell density in the differentiation 
cultures, without a statistically significant frequency. On the other hand, the same cell 
lines were also able to display mineralization, observed by Alizarin red staining, confirming 
osteogenic differentiation ability (Fig. 31B). The same results were observed at late 
passages for all cell lines (data not shown). 
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Figure 31 Multipotency differentiation ability of MSCs 
MSCs untransfected (MSCs unt), clone #A1, clone #B12 and Mock (MSC.Mock) were cultured in vitro in (A) 
adipogenic or (B) osteogenic media, at passage 22. The cells were fixed and stained with Oil Red O 
(adipogenesis) or Alizarin Red (osteogenesis) for adipocyte or osteoblast differentiation. Cells cultured in 
normal medium were use as control. Scale bars = 50 μm (adipogenesis) and 100 μm (osteogenesis). 
 
 
Taken together these data demonstrate that the stable transfection with the selective 
pressure of the antibiotic G418, and the constitutive Db-scTRAIL secretion do not alter the 
typical phenotype, the specific markers expression and the multipotency ability of MSCs, 
even during long-term in vitro culture. Consequently, this confirms the advantages and 
safety of this novel cell based therapeutic approach for tumor treatment. 
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3.2.6 In vivo studies: MSC.TRAIL administration for tumor 
treatment 
 
After completion of the in vitro characterization of MSCs.TRAIL clones #A1 and #B12, 
both were used for in vivo studies to assess their potential therapeutic activity. First, 
MSCs were subcutaneously (s.c.; 4x106 cells) or intravenously (i.v.; 1x106 cells) injected 
in nude mice, using 4 mice for each group (clone #A1, clone #B12, MSC untransfected, 
Mock and PBS). The blood was collected from the tail vain after 1, 3, 7, 14 and 21 days 
and the serum fraction was used in order to test the presence of Db-scTRAIL by ELISA 
(Fig. 32).  
In the intravenous administration approach for both MSC.TRAIL clones, #A1 and #B12, 
for all the time points analyzed, no fusion protein could be detected in the serum, (data not 
shown). This negative result probably relates to a technical issue, due to the small number 
of cells that have been applied using i.v administration. Concerning the subcutaneous 
administration no TRAIL signals were revealed in the serum after 1 and 3 days whereas 
after 7 and 14 days fusion protein was detected in the range of 1,5 ng/ml for clone #B12. 
Surprisingly, despite comparable in vitro productivity, s.c. injection of clone #A1 did not 
result in detectable Db-scTRAIL levels. Whether this was a failure of engraftment or due 
to others reasons remained unresolved. As expected, all control cell injections gave no 
positive signal in ELISA. Based on these data clone #B12 was chosen for further in vivo 
experiments.  
 
 
Figure 32 Analysis of Db-scTRAIL production from MSC clones #A1 and #B12 s.c. injected in vivo  
MSCs untransfected, clone #A1, clone #B12, MSC.Mock cells (4x10
6
) were subcutaneously injected in one 
flank of a nude mouse (n=4 animals for each group, ± 95% CI) or 100 μl of PBS (s.c.) as control. After 1, 3, 7, 
14 and 21 days serum concentration of Db-scTRAIL was analyzed by ELISA assay. The groups: clone#A1, 
MSC unt, MSC.Mock and PBS did not revealed detectable protein levels. 
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Given the detected Db-scTRAIL concentration in the serum (1,5 ng/ml), and assuming 2 
ml as total blood volume in mouse, as reported by Schmidt and Wittrup (Schmidt and 
Wittrup, 2009), the estimation of total amount of protein in the circulatory system is 
approximately 3 ng, which corresponds to 32,26 nM. Comparing this result with the EC50 
values of Db-scTRAIL alone or in combination with BZB obtained in vitro on Colo205 cells, 
respectively 0,019 nM and 0,0022 nM (Fig. 17), the amount of protein in the blood is 
higher than the range necessary to observe an efficient bioactivity of Db-scTRAIL. 
Next, the antitumor activity of clone #B12, in xenograft tumor model, in which #B12 cells 
were peritumorally (p.t.) injected, was investigated. Figure 33 shows the experimental 
settings and the different groups of treatments tested. In particular, 4 nude mice for each 
group were subcutaneously injected with 3 million Colo205 tumor cells at both dorsal 
sides. The treatments started 10 days post tumor cell inoculation, when tumors were 
palpable and vascularized, reaching a volume of approximately 100 mm3. At this time 
point the first MSCs #B12 injection (4x106 cells in 100μl PBS, single injection) was 
performed. Mock cells and PBS served as control. In the combination treatment groups 
(see figure 33, groups 2 and 4), 5 μg of BZB were intraperitoneally (i.p.) co-injected every 
other day during the entire period of treatments. The second and the third MSCs injections 
were performed, as described above, after 17 and 27 days respectively. Tumor growth 
was monitored as described (Schneider at al., 2010 and Kim et al., 2011) every 2 or 3 
days. 
 
 
 
 
 
Figure 33 Scheme of MSC administration for tumor treatment in vivo  
NMRI nu/nu mice, 9 weeks old, were injected subcutaneously (s.c.) with 3x10
6
 Colo205 cells in 100 μl PBS at 
left and right dorsal sides. Treatments started 10 days after tumor cell inoculation when tumors reached ~ 100 
mm
3
. Mice received 3 injections of MSCs (4X10
6
 cells/injection p.t., red arrows), at the indicated time points. 
After the first MSCs injection mice from groups 2 and 4 received 5 μg Bortezomib (BZB) in 100 μl PBS 
intraperitoneally (i.p.), every second day.  
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Up to 2 weeks after the first MSCs injection no differences were observed in tumor growth 
between the 4 treatment groups. However, from day 17 on, coincident with the second 
MSCs administration, a slight but increasingly significant reduction of tumor size was 
observed for the combination treatment group clone#B12 plus BZB, up to day 26 (Fig. 
34A). At this time, DbαEGFR-scTRAIL was detectable in serum of both animal groups 
receiving #B12 cells (Fig 35A; 1,5 ng/ml). The second MSC injection was more efficient, 
probably, due to a cumulative effect with the first one. In fact, this is in accordance with 
the previous ELISA results in vivo, without established tumor (Fig. 32), where serum Db-
scTRAIL levels were detectable only 7 and 14 days after s.c. injection.  
Next, a third MSCs administration was performed and even if it did not produce a 
complete remission of tumors, it induced a stronger and more significant tumor size 
reduction for the group clone#B12 + BZB (Fig. 34B; p<0,001; day 31). The combination 
group Mock + BZB did not significantly interfere with the tumor growth (Fig. 34B), nor did 
monotherapy with bortezomib at the used dosage as reported by Siegemund et al., 2012. 
Of note, mice treated with clone#B12 in the absence of sensitizer BZB did not show any 
significant antitumoral effect, corroborating the in vitro data. This indicates that in the 
tested experimental conditions in vitro and in vivo the dosage of Db-scTRAIL secreted by 
MSCs, is apparently not sufficient to induce a significant antitumoral effect on its own, but 
is highly active in the presence of the apoptosis sensitizer bortezomib.  
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Figure 34 Antitumoral activity of MSC clone #B12 cells in a Colo205 xenograft tumor model  
(A) Tumor volume was analyzed as a function of time after p.t. injection of: PBS (green line), Mock+BZB (blue 
line), clone #B12 (orange line) or clone #B12+BZB (red line). Arrows, MSCs p.t. administration; asterisks, 
Bortezomib application; symbols, mean of tumor volumes ± 95% confidence interval (CI), n=8 
tumors/treatment group. (B) Individual tumor volumes at day 31 (n= 6 tumors for PBS group and n=8 tumors 
for Mock+BZB, cl#B12 and cl#B12+BZB). Bars, mean of tumor volumes ± 95% CI. 
 
 
Furthermore, in order to get insights into potential off-target, systemic side effects of 
continuous DbαEGFR-scTRAIL expression in tumor bearing animal, liver enzyme values in 
blood were determined, too, as an established indicator of liver toxicity. Toward this end, 
serum alanine aminotransaminase (ALT) levels were assayed in tumor bearing mice at 
day 31, after three MSCs p.t injections (Fig. 34B). The analysis showed for all groups 
mean serum ALT activities under the baseline (50 U/L), resembling the physiologic level in 
men (Fig. 35B). Accordingly, this result revealed that MSCs administrations did not induce 
discernable hepatotoxic effects in vivo, in accordance with a recent study from Yan and 
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colleagues (Yan et al., 2016). Additionally, all the other standard parameters, such as 
body weight, remained in the normal ranges for the entire period of treatment (data not 
shown). 
  
 
 
Figure 35 In vivo tolerance of MSCs administration 
(A) DbαEGFR-scTRAIL mouse serum levels were analyzed at day 26 by ELISA assay (mean ± S.E.M., n=3). (B) 
Alanine aminotransaminase (ALT) activity was analyzed in mouse serum, at day 31, after 3 MSCs p.t. 
injections (mean ± S.E.M., n=3). Positive control, 0.1 nmol Fas ligand fusion protein; negative control, PBS; 
dotted line, upper normal level (50 U/L). 
 
 
Finally, the overall survival for each group was followed for up to 52 days. As shown in 
figure 36, the mice in the control group (PBS) could not survive over 33 days due to fast 
tumor growth necessitating sacrification when tumor volume reached ~ 1100 mm3. The 
other two control groups, clone#B12 and MSC.Mock+BZB, showed a survival rate at day 
52 of ~50% and ~60%, respectively, indicative of a partial response to each of the drugs 
when given as monotherapy. In accordance with the direct determination of tumor size at 
day 31, a higher survival rate of around 80% was observed for the group with the 
combination treatment clone#B12, secreting Db-scTRAIL, and BZB.  
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Figure 36 Analysis of survival rate after MSCs administration 
Analysis of survival rate for all groups of treatment was conducted using a log-rank test based on Kaplan-
Meier method. Mice were sacrificed when tumor volume reached ~ 1100 mm
3
. 
 
 
In conclusion, together these results demonstrate that stable transfection of MSCs, with  
DbαEGFR-scTRAIL, using a non-viral method is an efficient cell delivery system for anti 
cancer proteins both in vitro and in vivo. In particular, multiple injections of MSCs in 
mouse model did not show hepatotoxic or general side effects, but a significant tumor 
reduction in combination with bortezomib. Together, the in vivo analysis provides proof of 
concept that in situ expression of a tumor targeted TRAIL variant by locally administered 
stable MSC transfectants is a safe and effective means of combating tumor growth. 
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4. Discussion 
 
 
Stem cells have generated a great deal of interest, since their first identification in 1963 by 
McCulloch and Till (Becker et al., 1963 and Siminovitch et al., 1963) due to their unique 
properties such as multi lineage differentiation potential and immunomodulation ability. 
The discovery of cancer stem cells (CSCs) (De Maria et al., 2007), which derived from 
normal SCs after genetic and epigenetic mutations, opened new sceneries in the field of 
tumor therapy. In fact, several studies have suggested that CSCs are responsible for: 
tumor initiation, metastasis formation and tumor recurrence after treatment (Todaro et al., 
2010). The failure of canonic and standard cancer therapies is attributed to CSCs, which 
represent only a small fraction of the tumor cell population. Consequently, identification 
and targeting of these cells, within the tumor mass, is crucial to improve outcomes of 
current tumor treatments.  
Toward this end, in the first part of this study I generated new scFv-scTRAIL fusion 
proteins targeting CD133 and LGR5, which represent two of the most promising colon 
CSC markers (Ricci-Vitiani et al., 2007 and Barker et al., 2008). On the other hand, adult 
stem cells, like MSCs, can be isolated from different sources in the human body such as 
bone marrow, umbilical cord or adipose tissue (Kern et al., 2006) and applied for clinical 
treatments. Although, in regenerative and transfusion medicine MSCs are already used 
and accepted for therapeutic approaches (Lazarus et al., 1995 and Horwitz et al., 1999), 
additional applications such as in cancer treatment are currently exploited, in part as cell 
based carrier systems for local expression of peptide or protein therapeutics (reviewed by 
Stuckey and Shah, 2014). Typically, expression of the therapeutic is upon viral 
transduction and under control of strong viral promoters (Yu et al., 2013 and Grisendi et 
al., 2015), which has raised safety concerns. For this reason, in the second part of this 
work I established a MSC line with non-viral transfection method displaying stable 
expression of a highly bioactive EGFR targeting Db-scTRAIL fusion protein (DbαEGFR-
scTRAIL). This cell line showed potent apoptotic induction in vitro and retained its 
mesenchymal characteristics. Furthermore, in xenotransplantation mouse tumor models I 
could demonstrate a significant antitumoral activity of DbαEGFR-scTRAIL produced by MSC, 
in combination with Bortezomib, when transplanted into the vicinity of established, 
vascularized tumors. Finally, I showed that the MSCs administration is a safe procedure 
confirmed by the absence of hepatotoxic effects in the animals. 
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4.1 Db-scTRAIL fusion proteins targeting CSC markers 
 
In oncology TRAIL-based therapies were extensively studied, in clinical trials in a broad 
range of different tumors, yielding very disappointing results (reviewed by Lemke et al., 
2014). There are three major critical aspects that were investigated in order to improve the 
therapeutic benefits of these therapies. The first one is based on the low in vivo bioactivity 
observed for recombinant TRAIL molecules and their short plasma half-lives (Herbst et al., 
2010 and Soria et al., 2010). In order to overcome this limitation, the proapoptotic ligands 
were engineered to exert stronger antitumor activity by creation of single-chain molecules 
(Krippner-Heidenreich et al., 2008). The second one is the intrinsic or acquired resistance 
to TRAIL activity observed in several tumor cell lines (Maksimovic-Ivanic et al., 2012). 
This obstacle can be overcome by combined therapy based on the sensitization of the 
tumor cells to TRAIL function by different reagents. The list of TRAIL sensitizers, which 
showed a significant increase of apoptosis induction, includes the proteasome inhibitor 
bortezomib (de Wilt et al., 2013) and the small molecule Smac mimetic which mimic the 
XIAP binding site (Fakler et al., 2009 and Lecis et al., 2010). The last critical aspect that 
has to be considered to improve the TRAIL anticancer effects, is an active targeted 
delivery of this proapoptotic protein to the tumor cells, resulting in enhanced local 
concentration and reduced dilution of the protein in circulation. In fact, several studies 
reported that TRAIL protein can be engineered to induce a stronger antitumoral activity, in 
vitro and in vivo, by targeting specific cell surface-expressed tumor antigens (Seifert et al., 
2014 and Siegemund et al., 2016).  
 
Based on these concepts and on the new findings concerning the key role plays by CSCs 
in tumorigenesis and cancer resistance, I generated two Db-scTRAIL fusion proteins 
exhibiting target antigen binding domains (scFv) for the cancer stem cell markers CD133 
and LGR5 (#DbαCD133-scTRAIL and #DbαLGR5-scTRAIL). Even if a unique colon cancer 
stem cell marker is not yet available, CD133 and LGR5 seem to be the most promising 
candidates to specifically identify CSCs within the tumor as reported by Catalano et al., 
2012 and Barker et al., 2013. In particular, CD133 is broadly expressed in colon cancer 
cells lines as I confirmed by flow cytometry analyses, showing a significant high 
expression of the marker on 3/4 colon cancer cell lines tested. However, LGR5 expression 
was detected only in 1/4 cell lines. This difference is probably due to the fact that the 
expression of LGR5 is restricted only at the base of the intestinal crypts and not in the 
entire tissue as reported by Barker and colleagues (Barker et al., 2007).   
For both fusion proteins a dimeric scTRAIL configuration was designed and achieved, as 
demonstrated by the size exclusion chromatography. Furthermore, the binding of the 
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TRAIL fusion proteins to the respective target antigens were tested and confirmed via flow 
cytometry. In fact, the analysis revealed, for both proteins, a concentration of half-
maximum binding (EC50) in the pM range. These results are in accordance with other 
studies which showed a specific CSCs identification using new antibodies targeting either 
CD133 or LGR5 (Kemper et al., 2012 and Kwiatkowska-Borowczyk et al., 2015). 
Additionally, the functional bioactivity of DbαCD133-scTRAIL and DbαLGR5-scTRAIL in cell 
death induction was analyzed and confirmed for both proteins. Interestingly, in 
accordance with previous investigations on colorectal cancer treatments (Siegemund et 
al., 2012 and Möller et al., 2014), the Db-scTRAIL activity was even more potent in 
combination with the respective sensitizers (bortezomib and Smac mimetic), resulting in a 
~4 fold increase of cell death induction for both fusion proteins. 
 
The targeting antigen effect on apoptosis induction for DbαCD133-scTRAIL and DbαLGR5-
scTRAIL was investigated. Previous studies reported a significant superior bioactivity, 
both in vitro and in vivo, for fusion proteins comprising a targeting scFv fragment and 
scTRAIL domains in comparison with nontargeted TRAIL proteins (Seifert et al., 2014 and 
Siegemund et al., 2016). This is probably due to the fact that tumor-targeted TRAIL fusion 
proteins can mimic the natural membrane-bound form of the ligand, allowing the activation 
of both TRAIL receptors (DR4, DR5) (Bremer et al., 2005 and Schneider et al., 2010). 
Nevertheless, in this work, a significant increase of TRAIL-mediated apoptosis induction 
for #DbαCD133-scTRAIL and #DbαLGR5-scTRAIL in comparison with nontargeted scTRAIL 
protein was not observed.  
This result might be due to two different reasons. The first one is only a moderate affinity 
of the scFv to the specific target and the second one could be the low antigen expression 
on the analyzed tumor cell lines. This latter, in particular, was observed for the marker 
LGR5. Recently, Garg and colleges reported that nontargeted TRAIL fusion protein, 
compare to targeting TRAIL, showed a much higher cell death induction on tumor cells 
that lack the antigen expression (Garg et al., 2014). This result suggests that the targeting 
domain, in this case, exhibits even a negative effect on the protein activity. Additionally, 
unpublished data, communicated by  Meike Hutt (Institute of Cell Biology and 
Immunology, Stuttgart), revealed for some, but not all xenograft tumor models, only 
comparable, but not superior bioactivity of targeting vs. structurally similar non-targeting 
fusion proteins . These data are in accordance with the in vitro results of the present 
study. In conclusion, a superior activity of targeted TRAIL fusion proteins is probably only 
achieved when the affinity of the fusion protein towards the target antigen or the antigen 
density at the tumor cell membrane is significantly higher compared to TRAIL receptors. 
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4.2 Mesenchymal stem cell as delivery vector for the expression 
of Db-scTRAIL therapeutic protein 
 
In this part of the study I investigated and confirmed the potential use of MSCs, isolated 
from bone marrow, as delivery system for the expression of the pro-apoptotic protein 
DbαEGFR-scTRAIL. Several reports show, in fact, that MSCs can be genetically modified to 
express different antitumoral agents, such as IL-12 (Shrayer et al., 2002), IFN-β (Studeny 
et al., 2002) or IL-2 (Stagg et al., 2004). When these MSCs were applied in tumor models, 
significant tumor growth reduction and even complete remissions were reported.  
At the beginning of this work, the MSCs insensitivity to TRAIL activity, even in combination 
with sensitizers (bortezomib and smac mimetic), was verified. As reported by Szegezdi et 
al. 2009, apoptosis resistance is not due to a lack of TRAIL receptors expression, but to 
the fact that DR4 and DR5 are both inactive in MSCs. In this study they examined TRAIL 
sensitivity testing three MSC lines, isolated from different sources: bone marrow, fetal 
blood and umbilical cord. All the cell lines resulted insensitive to apoptosis induced by 
human recombinant TRAIL, despite the expression of DR4 and DR5, suggesting that this 
is probably a general characteristic for these stem cells lines.  
MSCs were transiently transfected and DbαEGFR-scTRAIL secreted in the medium showed 
a significant reduction of cell number in colon cancer cells (Colo205), in a DbαEGFR-
scTRAIL dose dependent manner. The superior pro-apoptotic activity of TRAIL in the 
presence of bortezomib is in accordance with several studies revealing synergistic activity 
in a broad range of different cancer models (reviewed by de Wilt et al., 2013). 
Viral vectors are the most used systems to introduce genes into stem cells, even if the 
safety of these methods, for clinical applications, is still under controversial debate. This is 
due to the fact that some of these viral vectors, like lentiviruses, are immunogenic and 
show instability of the transgene, which can cause severe immune responses when 
introduced into the patients (reviewed by Stuckey and Shah, 2013). Additionally, the 
specific integration site of the vector DNA into the genome of the cells is crucial and it 
should not be random, because in case of disruption of genes necessary for essential 
cellular processes stem cells might themselves generate tumors. Although the existence 
of all these critical concerns about safety of viral method, probably due to the higher 
efficiency of this system, only a small number of studies have used non-viral method to 
transfect SCs (Choi et al., 2011 and Hu et al., 2012).  
For this reason, in order to extend knowledge about the potential use of non-viral 
transfection approach, which can be easily be translated into clinical applications, in this 
study a non-viral transfection method based on Polyethyleneimine (PEI) was used. 
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The success of this transfection method in terms of stable and long expression of a 
bioactive Db-scTRAIL secreted by MSCs was achieved by the selection of MSC clone#A1 
and clone#B12. The ELISA analyses confirmed a stable production up to passage 42 
while the co-culture of MSC.TRAIL and Colo205 cells demonstrated the bioactivity of the 
secreted protein. Interestingly, the reduction of cell viability induced by the different ratios 
of MSC.TRAIL and Colo205 co-cultured was not tightly correlated to the exact number of 
MSC.TRAIL used, but was generally a bit higher than expected. This is probably due to an 
intrinsic limitation of the in vitro co-culture assay in comparison with application of soluble 
proteins into the cell medium. In this case, in fact, an equal distribution of the therapeutic 
molecule in the total culture volume can be reasonably assume. While during co-culture 
experiment, only a random distribution of “producer” MSCs and cancer cells can be 
achieved. In this context, consequently, is extremely hard to observe a tight dose-
response effect based on the different ratios of the cells. The same effect was also 
reported in different studies testing the bioactivity of TRAIL molecules, secreted by MSCs, 
in different tumors such as ovary, lung, colon and pancreas derived cancer cell lines (Yu 
et al., 2013; Yuan et al., 2015; Grisendi et al., 2015).  
 
In the last several years, the tumor homing ability of MSCs was tested and reported for a 
broad range of different cancer cell lines including breast cancer (Kidd et al., 2009), 
melanoma (Studeny et al., 2002), colon cancer (Menon et al., 2007), Kaposis’s sarcoma 
(Khakoo et al., 2006), malignant glioma (Sasportas  et al., 2009), ovaric cancer (Kidd et 
al., 2009) and lung cancer (Loebinger et al., 2009). However, the specific molecular 
mechanism which regulates the migration of MSCs across the endothelium to reach tumor 
sites is not yet completely elucidated. Several molecules have been analyzed and 
proposed as putative candidates which are responsible for integration of MSCs into tumor 
stroma, in particular chemokines and growth factors (Momin et al., 2010). In the present 
study I tested the migratory ability of MSCs, transfected and untransfected, in response to 
EGF, IGF-1 and Colo205 cells. In accordance with Ponte et al., the established clonally 
derived MSCs lines, clone#A1 and clone#B12, maintained the ability to migrate in 
response to both growth factors EGF and IGF-1 in vitro, in a manner that is comparable 
with untransfected MSCs (Ponte et al., 2007). While surprisingly all the MSC lines, 
included the untransfected cells, were not able to migrate when Colo205 cells were 
seeded in the lower chamber of the transwell. This can be due to the fact that the number 
of Colo205 cells used in this experimental condition did not secrete a sufficient amount of 
growth factors in the culture medium. In fact, seeding the same number of Colo205 cells, 
no detectable levels of EGF after either 8 or 18 h of cultivation were observed (data not 
shown). However, a comparable migratory (or non-migratory) capacity was observed 
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between untransfected and transfected MSC lines, demonstrating that the stable 
transfection did not interfere with this specific MSCs’ ability.  
 
Nevertheless, the migratory capacity of the MSCs as well as the bioactivity and the 
expression rate of the pro-apoptotic protein are not the only aspects that have to be 
considered and verified in stem cell based gene approach. In fact, MSCs used as cell 
delivery system must maintain their stemness properties after gene expression. The three 
minimal criteria to define MSCs were determined in 2006 by the International Society of 
Cellular Therapy (ISCT) (Dominici et al., 2006). First, MSCs must be adherent to plastic 
under standard culture condition. According to the second one, MSCs must express 
certain cell surface markers, including CD9, CD44, CD71, CD90, CD105, and lack 
expression of other markers like CD14, CD34 or CD11b. The last criterion verifies the 
multipotency ability of MSCs which must maintain the capacity to differentiate into 
adipocytes, chondroblasts and osteoblasts in vitro. In accordance with the first criteria, 
both clonal MSC lines (clone#A1 and clone#B12) grown in adherent condition and shown 
always during the different passages (p 14, p 25, p 42) a typical spindle-shaped 
phenotype as confirmed by immunofluorescence analysis using phalloidin to visualize F-
actin. Furthermore, in line with the second criteria all MSC lines stably transfected 
maintain the expression of specific cell markers, like CD9, CD44, CD71 and CD105, and 
on the other hand they didn’t express CD14 and CD34. In accordance with these results, 
most of the surface markers expressed on these MSCs transfected with Db-scTRAIL have 
been described also by other groups using mouse MSCs (reviewed by Boxall and Jones 
2012). Finally, even the last criterion defined by the ISCT was confirmed for all 
untransfected and transfected MSC lines, which maintained over passages the ability to 
differentiate into adipocytes and osteocytes. Additionally, all these results, concerning the 
MSCs characterization, are also in line with the study published by Raeth et al., 2014, who 
could show that this very same murine MSC line is capable of  in vivo bone formation. 
 
Taking together these data demonstrate that the MSC lines generated here are 
characterized by stable, long term expression of the anti-tumoral agent, DbαEGFR-scTRAIL, 
which induces strong apoptotic activation on colon cancer cells in combination with the 
sensitizer bortezomib. More importantly, expression of the fusion protein did not alter or 
interfere with the typical MSCs properties, even upon long term cultivation. This is an 
essential starting point for translation of stem cell based gene therapy in clinical 
applications. 
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4.3 Mesenchymal stem cell based therapy for cancer treatment in 
vivo 
 
Despite all the extensive studies performed in the past decades in order to improve 
outcomes of cancer treatments with non-antibody biologics, such as interleukins, 
proapoptotic and immune-stimulating cytokines, there are still limitations which reduce the 
potential efficacy of this class of anticancer agents. The major drawbacks of conventional 
treatments as well as those of new biological reagents include off target actions and 
potential systemic side effects, and/or inadequate biodistribution/bioavailability due to 
short plasma half-life and fast renal clearance of the specific agents after administration 
(Herbst et al., 2010 and Soria et al., 2010). But the discovery of adult stem cells which 
show intrinsic tumor tropic properties to several cancer types (Sasportas  et al., 2009; 
Loebinger et al., 2009; Kidd et al., 2009), opened new avenues for tumor treatment using 
stem cell based gene therapy. This novel approach can overcome the major limitations of 
the conventional treatments like biodistribution and short half-life. In fact, as reported by 
several studies using different therapeutic agents including IFN-β (Studeny et al., 2002), 
IFN-α (Ren et al., 2008) and IL-12 (Shrayer et al., 2002), the use of SCs as delivery vector 
produce a significant increase of local concentration of the antitumoral agents around the 
tumor. This increased concentration resulted in a more efficient antitumoral activity of the 
therapeutic agents than the same molecules used in a systemic administration treatment. 
Importantly, an efficient translation of cell based therapy into clinical application requires 
the ability to readily administer a safe and efficacious product at the optimal dosage. 
Toward this aim, two sources of stem cells can be considered, autologous material from 
the patient and allogeneic material from healthy donors. Despite the fact that allogeneic 
therapy is, in principle, a disruptive concept in immunology due to the dogma of immune 
reactions to any foreign tissue, allogeneic MSC based gene therapy potentially offers 
enormous advantages over autologous systems. It is  an efficient way to achieve 
immediate availability of well characterized cells in appropriate quantities. Strong 
alloreactivity is clearly a major hurdle in solid organ and hematopoietic transplantation, 
necessitating strong immunosuppression to protect the allograft from rejection (Chinen et 
al., 2010). However, MSCs surprisingly evade immune recognition or even actively 
suppress immune response (van den Akker et al., 2013) suggesting that they can be used 
as allografts without requiring simultaneous immunosuppression. Moreover a clinical 
application of autologous MSCs could have some critical limitations compared to an 
allogeneic, well characterized MSC producer line. In fact, when an autologous source is 
used, the MSCs derive from a patient that is generally older and with multiple 
comorbidities and the final product is manufacturing dependent and limited in term of 
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available healthy cell number. Furthermore, it was recently reported that MSCs derived 
from elderly donors, revealed decreased biological activities, including regenerative and 
differentiation potential, resulting in disappointing treatment outcomes (Jung et al., 2014). 
Isolating allogeneic MSCs from healthy young donors can overcome these issues. The 
allogeneic MSCs  in fact, can be expanded to a larger amount, undergo pre- and post- 
cryopreservation control of viability and can be immediately available for administration 
with the necessary cell number. A recent interesting publication, from Lorkeers et al., 
reported a comprehensive meta-analysis of large animal studies comparing the effects of 
autologous and allogeneic stem cell therapies, in ischemic heart disease (Lorkeers et al., 
2014). Analyzing the 82 publications included in the study, they conclude that stem cell 
based treatments appear to be safe and that autologous and allogeneic therapy exhibit 
similar effects. Even if several questions are still open such as the optimal cell delivery 
method  or the cell dosage range, the allogeneic cell therapy represents a promising 
alternative for clinical treatments of different disease including cancer. 
Based on these concepts, I generated stable MSC lines producing the proapoptotic TRAIL 
fusion protein, clone#A1 and clone#B12, and investigated their usefulness for tumor 
treatment in a xenograft mouse model. Usually, in vivo models for tumor therapy using 
MSCs as delivery vector requires multiple injections of the cells during the time of 
treatments. In fact, as recently reported by Grisendi et al., and Yu et al., a significant 
tumor reduction or a complete remission can be achieved only after multiple injections of 
MSCs expressing TRAIL, independently on the method of cell administration (Yu et al. 
2013 and Grisendi et al. 2015). In contrast, in this work, a significant reduction of tumor 
volume was observed already after two peritumorally administrations of MSC.TRAIL 
(clone #B12), in the presence of bortezomib, in comparison with all the other treatments 
groups. Additionally, the ELISA assay performed after the second administration (day 26), 
revealed TRAIL levels in the serum of mice injected with MSC.TRAIL cell line. This result 
suggests a correlation between the significant reduction of tumor size and the TRAIL  pro-
apoptotic bioactivity.  
In the present study the i.v administration of MSCs did not result in detectable TRAIL 
levels in the serum as observed for the s.c. injection. The main reason is probably the 
lower number of cells that were applied in this particular experiment due to technical 
limitations. However, because this approach was performed only once it is not possible to 
conclude that i.v. is not a feasible approach. In fact, in literature several publications 
reported an efficient antitumoral effect after i.v. injection of MSCs, even using less than 1 
million cells (Yu et al., 2013). Another unexpected finding was that clone#A1, when s.c. 
injected, showed no detectable production of TRAIL in vivo, in contrast to the positive 
result with clone#B12, despite that in all in vitro analyses both clones showed similar 
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productivity and bioactivity. The reason of this result is unclear, it probably can be due to 
the fact that the cells were not able to find/establish the proper conditions for an efficient 
production in vivo, or might have been due to a technical problem. Nevertheless, based 
on this single assay is not reasonable to conclude that the clone#A1 is inactive in vivo, 
additional experiments are required to clarify this issue.  
A critical aspect of the cell based therapy is its safety. In this work, this aspect was 
investigated by analyzing the alanine transaminase levels in the serum as a measure of 
acute liver toxicity and by measuring body weight, with no evidence obtained for such 
adverse, therapy limiting effects. The results are in accordance with other publications that 
used TRAIL as therapeutic protein, secreted by MSCs, for treatments of different tumors 
such as lung (Yan et al., 2016) and colon cancer (Yu et al., 2013).  
With the applied therapy scheme, after 42 days of treatments tumors started to regrowth, 
except for 3 tumors in the cl#B12 + BZB group which remain still responding with tumor 
volumes below 250 mm3 up to day 52, a state classifiable as stable disease. At this time 
point (42 days) TRAIL was no longer detectable in the serum by ELISA assay (data not 
shown). This is probably due to different reasons, one could be that the MSCs had 
differentiated and stopped TRAIL fusion protein production at this time point. This 
hypothesis would be in accordance with the ELISA results of the previous in vivo analysis, 
where after a single s.c. MSCs injection TRAIL was no longer detectable in the circulation 
after 21 days. An alternative explanation could be that the MSCs did not survive until day 
42. An indication that this hypothesis could be reasonable comes from the 
immunofluorescence analyses of tumor sections of all groups, even if these were 
performed at the end of the study (day 52) and not at day 42. Given the fact that NMRI 
mice express haplotype H-2q as described by Kökény et al. (Kökény et al., 2007), while 
murine MSCs used in this work are positive for H-2kb, as reported by Raeth et al., 2014. 
For MSCs detection in tumor sections a specific antibody which binds the H-2kb (MHC 
class I) alloantigen, and does not cross react with haplotype H-2q, was used. However, no 
MSCs presence could be identified with certainty in all tumor tissues analyzed, in 
particular due to a too strong background signal (data not shown). Grisendi and 
colleagues detected MSCs on tumor sections after three intratumoral injections (Grisendi 
et al., 2014). But in this case the mice were sacrificed and analyzed 6 days after the last 
MSC administration. In contrast, in the present study the animals were sacrificed 25 days 
after the third MSC injection, so the cells had either vanished by this time (more likely 
explanation) or migrated towards different regions. 
Even if further investigations are necessary to address the open questions, the stem cell 
based therapy appears a promising tool for clinical application in tumor treatment. This 
method potentially offers, aside from achieving tumor responses, additional benefits for 
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the patients, for example in terms of frequency of therapeutic injections. In fact, the 
current standard treatments with purified proteins require daily injections or at least every 
second day. While based on the obtained results using MSCs, a regimen with a much 
reduced frequency of applications, weekly or even less frequent, seems achievable. In 
addition one can assume that the anticipated tumor localized production of the therapeutic 
is less prone to raise unwanted systemic side effects as noted in systemic clinical 
application of highly active biologics. This could improve patient compliance very much.  
 
In conclusion, in the preset study proof of concept was revealed that a stable and well 
characterized MSC line expressing therapeutic protein can be generated and when used 
in allogeneic transplantation in vivo induces a significant tumor response without side 
effects. 
In future studies it would be interesting to detect the biodistribution of transplanted MSCs 
after systemic injection and their in vivo fate, in order to verify the tumor homing ability.  
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5. Supplementary figures 
 
Dot blot analysis of single cell cultures for DbαCD133-scTRAIL and DbαLGR5-
scTRAIL 
 
 
 
Figure S1 Dot blot analysis of single cell cultures 
After around 14 days of single cell cultivation, (A) for DbαCD133-scTRAIL and (B) for DbαLGR5-scTRAIL, culture 
medium from each well was analyzed by dot blot using a specific antibody against FLAG and  single clones 
were selected (red circles). The pool cell line for each fusion protein was used as negative control (green 
squares). 
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Sensitivity of LoVo cells to smac mimetic and bortezomib  
 
 
 
 
Figure S2 Analysis of LoVo sensitivity to smac mimetic and bortezomib 
Lovo were treated with serial dilutions of (A) smac mimetic (SM) with a starting concentration of 10 μM 
(titration 1:3) or (B) with BZB using a starting concentration of 500 ng/ml (titration 1:3). After 18 h, cell viability 
was determined using crystal violet staining and data were normalized using normal medium treated cells as 
control (mean ± S.E.M., n=3). 
 
 
 
 
MSC stable cell lines: proliferation assay 
 
 
 
Figure S3 MSC stable cell lines: proliferation assay 
MSCs untransfected, clone #A1, clone #B12 and Mock cells were seeded at the same cell density and every 
48 hours cell number was calculated using the Neubauer chamber and Trypan blue. (mean ± S.E.M., n=5). 
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MSCs markers expression 
 
 
 
 
 
 
 
Figure S4 Surface MSCs markers expression 
Analysis of MSCs markers expression: CD9, CD44, CD71, CD105, CD14 and CD34 at passages (A) 9 and 
(B) 42. Cells were stained with indicate antibodies and binding was analyzed by flow cytometry (red). 
Unstained cells were used as negative control (black). Y axis: number of events analyzed. 
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